Assessing Risk Factors for Cognitive Decline Using Electronic Health Record Data: A Scoping Review

Assessing Risk Factors for Cognitive Decline Using Electronic Health Record Data: A Scoping Review | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Assessing Risk Factors for Cognitive Decline Using Electronic Health Record Data: A Scoping Review Liqin Wang, Richard Yang, Ziqin Sha, Anna Maria Kuraszkiewicz, and 3 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4671544/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background : The data and information contained within electronic health records (EHR) provide a rich, diverse, longitudinal view of real-world patient histories, offering valuable opportunities to study antecedent risk factors for cognitive decline. However, the extent to which such records’ data have been utilized to elucidate the risk factors of cognitive decline remains unclear. Methods : A scoping review was conducted following the PRISMA guideline, examining articles published between January 2010 and April 2023, from PubMed, Web of Science, and CINAHL. Inclusion criteria focused on studies using EHR to investigate risk factors for cognitive decline. Each article was screened by at least two reviewers. Data elements were manually extracted based on a predefined schema. The studied risk factors were classified into categories, and a research gap was identified. Results : From 1,593 articles identified, 80 were selected. The majority (87.5%) were retrospective cohort studies, with 66.3% using datasets of over 10,000 patients, predominantly from the US or UK. Analysis showed that 48.8% of studies addressed medical conditions, 31.3% focused on medical interventions, and 17.5% on lifestyle, socioeconomic status, and environmental factors. Most studies on medical conditions were linked to an increased risk of cognitive decline, whereas medical interventions addressing these conditions often reduced the risk. Conclusions : EHR data significantly enhanced our understanding of medical conditions, interventions, lifestyle, socioeconomic status, and environmental factors related to the risk of cognitive decline. Alzheimer Disease Dementia Cognitive Dysfunction Risk Factors Electronic Health Records Figures Figure 1 Figure 2 BACKGROUND Alzheimer's disease (AD) presents a substantial global public health challenge, given its hallmark features of chronic cognitive and functional decline in older adults. The condition is commonly categorized into three stages based on cognitive impairment severity: preclinical, where individuals exhibit normal cognitive function with or without subtle concerns but have biological evidence of underlying AD; prodromal, marked by mild cognitive impairment (MCI); and the dementia stage, characterized by significant functional impairment affecting daily life. 1 , 2 As of 2023, a staggering 6.7 million Americans are living with AD in its dementia stage, with projections estimating this number to soar to 88 million by 2050. 3 This not only poses a substantial financial burden but also profoundly impacts affected individuals, their families, and the healthcare system. Consequently, there is an urgent need to comprehensively grasp the risk factors associated with dementia and identify potential prevention and treatment strategies to mitigate this growing concern. Existing studies have frequently relied on prospective datasets, which tend to suffer from limitations such as small sample sizes and underrepresentation of understudied populations, resulting in notable gaps in ADRD research. 4 , 5 There is a growing consensus in the scientific community on the necessity of exploring more extensive and diverse populations. 1 Electronic Health Record (EHR) data have proven pivotal in understanding the progression and outcomes of neurodegenerative diseases, particularly due to their chronic and gradually advancing nature. The widespread adoption of EHRs over recent decades has yielded a vast amount of longitudinal patient data. By sifting through these real-world datasets, we can gain deeper insights into the onset and evolution of AD and related dementias (ADRD), especially among populations that have been consistently engaged with the healthcare system. EHRs can be valuable in identifying potential risk factors for ADRD that might be missed in smaller convenience sample datasets. Moreover, they can highlight interventions that target certain medical problems that potentially affect the risk of dementia, particularly during early stages such as preclinical AD and MCI. However, the extent to which EHR data have been utilized for such research remains unclear. While prior literature reviews have primarily focused on specific ADRD risk areas, 6 – 8 none, to our knowledge, has specifically addressed the utilization of EHR data for analyzing ADRD risks. Our study aims to fill this gap by concentrating on the identification of risk factors for cognitive decline, with a specific emphasis on MCI and dementia. We have intentionally excluded the preclinical stage of cognitive decline from our analysis due to diagnostic challenges in the clinical setting where biomarkers of AD are not commonly obtained prior to the stage of MCI. Through this scoping review, we aim to thoroughly aggregate existing literature on EHR data usage for studying these stages of cognitive decline and highlight potential areas for future research. METHODS Search Strategy This scoping review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 9 We conducted a Boolean search in PubMed, Web of Science, and CINAHL, identifying English-language studies published between January 1, 2010, and April 30, 2023. Our search included keywords related to cognitive impairment stages, such as dementia, MCI, and normal cognition, as well as EHR-related terms like “electronic health records”. The specific queries for individual databases can be found in Supplementary Table 1 . This study does not involve direct experimentation on human or animal subjects. All procedures and analyses comply with the ethical standards of the institution. Study Selection We included studies that utilized EHR datasets to investigate the association between potential risk factors and dementia outcomes. The EHR datasets referred to data extracted from EHR systems, not the active EHR systems themselves. We excluded review articles without original data, non-English articles, studies focused on patients with preexisting cognitive impairment at baseline, those with small sample size (n < 100) or short follow-up times (< 1 year), non-epidemiology studies (e.g., algorithm evaluation), and studies of low-quality with missing or unclear components (e.g., unclear diagnostic criteria for outcomes). Screening Process After eliminating duplicates and using automation tools (e.g., classification by the search engine, keyword-based search of the tile and abstract) to exclude articles deemed ineligible, we obtained abstracts from the search results. Two reviewers independently assessed titles and abstracts based on the inclusion and exclusion criteria, resolving disagreements through discussion to reach a consensus. Subsequently, two reviewers independently performed full-text screening, with a senior reviewer addressing any disagreements. Data Extraction We extracted articles assessing risk factors for the cognitive decline onset, including MCI, AD, and other dementias. We assessed methodological quality and developed a data extraction schema based on the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist for observational studies. 10 Extracted data included article information (authors and year), objectives, study design (e.g., cohort or case-control), study cohort, sample size, follow-up duration, data sources, explored risk factors, confounding variables, outcomes and measurement, statistical methods, and key findings. Each article underwent independent extraction by two reviewers, with discrepancies resolved through discussions, or consultation with a third reviewer. Article Classification After extracting risk factors from articles, we categorized them into major groups, including medical conditions, medical interventions, lifestyle, socioeconomic, psychosocial, and environmental factors. These groups were further subdivided; for example, medical conditions included cardiovascular and metabolic conditions, as well as psychiatric conditions. Some articles covered multiple risk factors, leading to overlap across categories. RESULTS Figure 1 shows the PRISMA flow diagram. The initial search yielded 1,593 articles, 565 from PubMed, 538 from Web of Science, and 490 from CINAHL. We removed 496 duplicate articles, where the same article appeared in more than one database. Automated tools marked 74 articles as ineligible, which included 3 case reports, 28 review articles, and 43 articles without abstracts. We also excluded 95 additional records, such as 42 datasets, 25 preprints, 13 authorless articles, 9 patents, 3 genetic studies, 2 books, and 1 thesis. Subsequently, during title and abstract screening, 832 articles were excluded for not meeting the criteria. The remaining 96 articles underwent full-text screening. After excluding additional 16 articles, e.g., those not primarily using EHR data, or having small sample size, 80 articles remained for final analysis. A detailed list of these articles and extracted data is available in Supplementary Table 2 in the supplement. Research Trend Over Time Figure 2 illustrates the distribution of analyzed articles by publication year. It shows a notable increase in publications related to our topic over the past decade, indicating a growing trend in using EHR data to examine ADRD risk factors. Although our search spanned from 2010 to 2023, all included articles were published after 2014. More than one-quarter of the articles (n = 22, 27.5%) were published in 2022. It is important to note that our search was conducted up to April 2023; therefore, the total for that year does not reflect the full annual count. Study Design Out of the 80 articles reviewed, 77(96.3%) were longitudinal studies retrospectively conducted, comprising 70 cohort studies, six case-control studies, and one randomized control trial. Longitudinal studies had a median EHR duration of 16 years, calculated from the initial year to the final year of the EHR records utilized, regardless of individual patient follow-up time. Among these, 16 studies (20%) had EHR data spanning under 10 years, 39 studies (48.8%) ranged between 10 and 20 years, and 22 studies (27.5%) had data duration exceeding 20 years. Methods for Statistical Analyses In the statistical analysis, 76.3% of the studies (n = 61) predominantly used survival analysis to model and identify various risk or protective factors. Among these, most (n = 54, 88.5%) opted for the Cox proportional-hazards regression model, 11 while some (n = 13, 21%) used the Fine-Gray model, 12 often in combination. The Fine-Gray model was chosen for its ability to handle competing risks like death. Other statistical analysis methods included logistic regression, Chi-squared test, and analysis of variance (ANOVA). EHR Datasets and Sources The included articles utilized diverse datasets to examine ADRD risk factors. These datasets were derived either directly from EHR systems, such as Veterans Health Administration (VHA), or linked to EHR databases to incorporate specific variables or outcomes from external databases, such as the UK Biobank. Categorized by geographical location, almost half of the studies (46.3%, n = 37) used data from EHR systems within the United States (US), while 40% (n = 32) utilized datasets from the United Kingdom (UK). Additional countries represented in this review included Australia (n = 3), 13–15 China (n = 3), 16–18 Denmark (n = 3), 19–21 the Netherlands (n = 3), 20–22 Taiwan (n = 2), 23, 24 Canada (n = 2), 25, 26 and Sweden (n = 2). 27, 28 In the US, the most frequently used EHR dataset was derived from the Kaiser Permanente’s EHR (11 studies), followed by the VHA (6 studies). The remaining 21 articles used databases from other US healthcare systems and commercial sources like TriNetX, 29 – 31 IBM Explorys, 32 and Optum. 33 For studies utilizing UK datasets, the Whitehall II study 34 – 39 (n = 8) and UK biobank 40 – 46 (n = 7) cohorts were the most frequently used, linked to various UK EHR datasets, including the Hospital Episode Statistics, 47 Scottish Morbidity Record data, 48 and Patient Episode Database. 40 , 41 , 46 Other frequently used databases in the UK studies included the Clinical Practice Research Datalink (n = 6) 49–53 and the Health Improvement Network (THIN) (n = 4). 21, 54 , 55 EHR Dataset Sample Size The studies employed datasets with varying sample sizes, from hundred to millions of patients. Only one study had fewer than 1000 patients. 25 Twenty-six (32.5%) studies had datasets ranging from 1,000 to 10,000 patients; 46 (57.5%) studies had datasets with 10,000 to one million patients. Seven (8.8%) studies used datasets with over one million patients. Outcomes and Measurements Most studies (n = 67) examined multiple dementia subtypes, including AD, vascular dementia, Lewy body dementia (LBD), frontotemporal dementia (FTD), and mixed dementia. AD was consistently included in all studies, with nine studies exclusively focused on AD. The majority of these studies defined outcomes using standard coding systems, such as ICD codes (81.3%, n = 65), Read codes (11.3%, n = 9), and SNOMED-CT (2.5%, n = 2). Additionally, some studies employed alternative methods, including prescriptions for dementia medications, 16 , 18 , 26 , 33 cognitive function tests, 25 , 42 , 56 referencing the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition), 22 , 57 , 58 screening interviews, 14 , 56 and neuroimaging. 42 Risk and Protective Factors We summarized the analyzed risk factors in the reviewed articles, categorizing medical conditions and interventions into broad disease categories (Table 1 ). Other risk factors were classified into lifestyle, socioeconomic, environmental, and miscellaneous categories (Table 2 ). Table 1 Summary of medical conditions and interventions from EHR-based studies in related to the risk of Alzheimer’s disease and related dementias. Medical conditions (n = 39) Medical interventions (n = 25) Categories No. of articles Risk Factors/Exposures No. of articles Risk Factors/Exposures Cardiovascular and metabolic 15 Diabetes↑ 23 , 26 , 35 , 60 , 61 Hypoglycemia in diabetic patients↑ 16 , 49 , 56 , 62 Hypertension↑ 23 , 61 , 63 , 64 ↔ 26 Hypotension ↑ 20 High blood pressure variability ↑ 65 Coronary artery disease ↑ 23 Stroke ↑ 23 Hyperlipidemia ↑ 23 Dyslipidemia ↔ 26 Obesity ↑ 53 ↓ 40 ↔ 26 11 Antihypertensive medications ↔ 26 Aspirin ↓ 30 Statins ↔ 26 Rosuvastatin ↓ 76 Anticoagulant ↓ 52 a Telmisartan ↓ 24 Metformin ↔ 77 ↓ 33 b Thiazolidinedione ↓ 78 c Sulfonylurea ↑ 33 , 78 c Metformin and thiazolidinedione dual therapy ↓ 78 c Sodium-glucose co-transporter 2 inhibitors ↓ 31 Carotid endarterectomy ↔ 27 Bariatric surgery ↑ 79 Infections, inflammatory, and immune-related 11 HIV ↑ 66 , 67 E. coli ↑ 68 e Herpes zoster ↓ 50 Covid-19 ↑ 29 Symptomatic herpes simplex virus infection ↓ 69 Common infections (sepsis, pneumonia, other LRTIs, UTIs and SSTIs) ↔ 42 Inflammatory/autoimmune conditions ↑ 45 Inflammatory Bowel Disease ↑ 32 High urate ↓ 40 Gout ↓ 55 5 Tumor necrosis factor blocking agent ↓ 32 , 80 Methotrexate ↓ 21 , 80 NSAIDs ↑ 51 Antiherpetic medication ↓ 19 Immunomodulators ↓ 32 Neurological/ophthalmological conditions 7 Retinal vascular occlusion ↑ 58 ↔ 71 Visual impairment ↑ 41 Diabetic retinopathy ↑ 72 ↔ 73 Traumatic brain injury ↑ 74 Epilepsy ↑ 75 1 Cataract extraction ↓ 57 Physical function and frailty 5 Low physical function ↑ 25 Physical inactivity ↔ 53 Underweight ↑ 20 , 26 , 40 ↔ 53 Low caloric intake ↔ 53 n/a Psychiatric 4 Depression ↑ 14 , 26 , 70 Psychotic disorder ↑ 15 4 SSRI ↑ 81 ↓ 76 Trazodone ↑ 54 e Benzodiazepines ↔ 22 Oncology 2 Cancer ↑ 45 Skin cancer ↓ 59 3 Androgen deprivation therapy ↑ 82 , 83 Aromatase inhibitor therapy versus tamoxifen ↔ 84 d Other 4 Kidney disease ↑ 23 , 36 Hip fracture ↑ 17 Osteoarthritis ↑ 26 3 β-antagonists ↓ 18 Vitamin D ↓ 43 Omeprazole ↓ 76 Table 2 Summary of lifestyles, socioeconomic, psychosocial, environmental and other factors from EHR-based studies in related to the risk of Alzheimer’s disease and related dementias. Categories No. of articles Risk Factors/Exposures Lifestyle, socioeconomic, psychosocial, environmental risk factors (n = 14) Lifestyle 5 Diet ↔ 37 , 85 Healthy lifestyle ↓ 44 Smoking ↑ 26 Alcohol consumption ↑ 28 Socioeconomic 5 High education ↓ 86 , 87 ↔ 38 Neighborhood disadvantage ↑ 26 , 88 Low occupational position ↑ 38 Psychosocial 2 Social isolation ↑ 46 Social contact ↓ 39 Feeling of loneliness ↔ 46 Environmental 3 Birth in high stroke mortality states ↑ 89 Agent orange ↑ 90 Lithium level in drinking water ↑ 91 Others (n = 8) Others 8 Plasma protein ↑ 34 Lower testosterone ↑ 13 Higher brain age ↑ 103 Low Childhood IQ ↑ 104 ICU admission ↑ 105 Hispanic race ↑ 61 Sex ↔ 26 CRP genotype ↔ 45 Apolipoprotein E (APOE) genotype ↔ 45 Medical conditions Out of the 80 articles reviewed, 39 (48.8%) explored the interplay between medical conditions and ADRD. Of them, 15 articles focused on cardiovascular and metabolic conditions, 11 on infections, inflammatory and immune-related conditions, 7 on neurological/ophthalmological conditions, 5 on physical function and frailty, 4 on psychiatric conditions, 2 on cancer, 45 , 59 and 4 on other risk factors like kidney disease, 23 , 36 osteoarthritis, 26 and hip fracture. 17 Cardiovascular and metabolic conditions : A significant finding in our analysis is the association of cardiovascular/metabolic conditions and ADRD risk. Diabetes, examined in several studies, 23 , 26 , 35 , 60 , 61 and its common complication, hypoglycemia, identified as a risk factor, 16 , 49 , 56 , 62 are noteworthy. Extensive research using EHR data has explored blood pressure’s relationship with ADRD. Hypertension, 23 , 61 , 63 , 64 hypotension 20 and blood pressure variability, 65 all contribute to increased ADRD risk. Additional risk factors include coronary artery disease, 23 stroke, 23 and hyperlipidemia. 23 Obesity’s impact is mixed: it has been identified as a risk factor in one study, 53 suggested to have a potential protective effect in another, 40 and found to have no impact in a third, 26 , 53 although this may be influenced by factors like age at assessment and frailty in underweight individuals. Infections, inflammatory and immune-related conditions HIV, 66 , 67 E. coli, 68 and Covid-19 29 have been identified as risk factors for ADRD. However, several common infections–such as sepsis, pneumonia, lower respiratory tract infections, urinary tract infections, and skin and soft tissue infections–did not exhibit increased ADRD risk. 42 Regarding herpes viruses, one study observed a slightly decreased risk of dementia among individuals with symptomatic Herpes Simplex Virus 1 (HSV-1) infections untreated by antivirals and a more pronounced 25% decrease in those treated with antivirals. 69 Another study detected a minor protective link between Herpes Zoster (HZ) and dementia, particularly in frail individuals and females, and only for mixed or unspecified dementia. 50 Additionally, the inflammatory/autoimmune disease cluster was associated with elevated ADRD risk, 45 including inflammatory bowel disease was also found as a risk factor. 32 Both high urate 40 and gout 55 were associated with a decreased risk for ADRD, possibly due to uric acid’s antioxidant effects, which align with observations related to obesity. 22 Psychiatric conditions The interplay between depression and ADRD remains unclear. While some view depression as a symptom, others see it as a precursor. In our final analysis, three articles explored the link, and all identified a depression as a risk factor for ADRD. 14 , 26 , 70 Additionally, psychotic disorders have been reported as a risk factor. 15 Neurological/ophthalmological conditions The eyes and brain also form crucial nodes in the ADRD risk network. Retinal vascular occlusion is linked to increased ADRD risk. 58 Visual impairment, assessed by visual acuity, has also been linked to an elevated ADRD risk, 41 although one study did not find this connection. 71 The impact of diabetic retinopathy, a complication from diabetes, remains ambiguous, with one study indicating increased risk 72 and another observed no effect. 73 Traumatic brain injury 74 and epilepsy 75 are identified as risk factors. Physical function and frailty Frailty metrics are factors to consider in ADRD risk assessment. Underweight is identified as a risk factor for ADRD, 20 , 26 , 40 although one study had a different finding. 53 The protective effect of obesity, sometimes observed, could be related to avoiding the increased risk associated with being underweight. 22 Low physical function, measured by grip strength and the Short Physical Performance Battery (SPPB), is linked to increased risk. 25 However, another study did not find an association between physical inactivity or unintentional low caloric intake and ADRD risk. Other medical conditions Several studies have investigated a miscellany of medical conditions in related to ADRD. Cancer is noteworthy, with one study showing an elevated ADRD risk in the cancer disease cluster. 45 In contrast, another study found that malignant melanoma and non-melanoma skin cancers were associated with a reduced ADRD risk, suggesting a protective effect. 59 Additionally, kidney disease, 23 , 36 hip fracture, 17 and osteoarthritis 26 were identified as ADRD risk factors. Medical interventions In light of the risk posed by medical conditions to ADRD, researchers have examined various medical interventions to determine if they could mitigate the risk of ADRD. Of the 80 articles assessed, 25 (31.3%) analyzed the association between medical interventions and ADRD. Out of these, 11 were related to cardiovascular and metabolic interventions, 5 to immune, infection, and inflammatory interventions, 4 to psychiatric interventions, 3 to oncology, and 4 to other interventions. Cardiovascular and metabolic-related interventions Research has focused on treatments targeting cardiovascular and metabolic conditions to reduce ADRD risk. Medications such as rosuvastatin, 76 telmisartan, 24 anticoagulants, 52 and aspirin, 30 primarily for cardiovascular health, have proven effective in lowering ADRD risk. In diabetes management, metformin showed no association with incident dementia compared to no initial treatment within the first 6 months post-diagnosis. 77 However, it presented a mild protective effect compared to sulfonylureas. 33 , 78 Conversely, thiazolidinedione monotherapy and combined therapy with metformin reduced ADRD risk compared to metformin alone. 78 Sodium-glucose co-transporter 2 inhibitors decreased the risk of dementia in patients with atrial fibrillation and type 2 diabetes. 31 Among surgical interventions, bariatric surgery increased ADRD risk, 79 while carotid endarterectomy had no discernible impact. 27 Immune, infection and inflammatory-related interventions Immune, infection and inflammatory-related interventions, such as tumor necrosis factor blocking agent, 80 methotrexate 21 and antiherpetic medications, 19 were found to have protective effects against ADRD, while nonsteroidal anti-inflammatory drugs (NSAIDs) 51 were observed to increase the risk. Psychiatric-related interventions Studies had contradictory conclusions on the impact of the selective serotonin reuptake inhibitor (SSRI) antidepressant class on ADRD risk, with one suggesting it as a risk factor 81 and the other as protective. 76 Trazodone, another serotonergic antidepressant often used for insomnia, was reported as a neutral factor. 54 Oncology and other Interventions Androgen deprivation therapy was linked to an increased risk for ADRD in two studies by the same team. 82 , 83 However, aromatase inhibitor therapy and tamoxifen, used for hormone receptor-positive breast cancer, did not show a difference in dementia risk. 84 Lifestyle, socioeconomic, psychosocial and environmental factors EHR data have been utilized to examine the influence of lifestyle, socioeconomic, psychosocial, and environmental factors on ADRD. Out of the reviewed articles, 14 (17.5%) were related to this topic, with 5 articles focused on lifestyles, 5 on socioeconomic factors, 3 on environmental factors, and 2 on psychosocial factors. Lifestyle Both smoking 26 and extensive alcohol consumption 28 were identified as risk factors for ADRD. Conversely, a healthy lifestyle, including no current smoking, moderate alcohol consumption, regular physical activity, healthy diet, adequate sleep duration, less sedentary behavior, and frequent social contact, exhibited a protective effect against ADRD in patients with type II diabetes. 44 However, diet alone was not found to be protective against ADRD. 37 , 85 Socioeconomic factors Higher education showed neuroprotective effects in two of three studies on education and ADRD risk, 86 , 87 although the third study found no significant correlation. 38 Neighborhood disadvantage 26 , 88 and low occupational position 38 were associated to a higher risk of ADRD. Psychosocial factors Psychosocial factors such as social isolation have been identified as risk factors for ADRD. 46 In contrast, frequent social contact appears to be a protective factor. 39 Another metric, the “feeling of loneliness,” was not associated with an increased or decreased risk. 46 Environmental factors EHR data was used to analyze several environmental risk factors for ADRD. Being born in high stroke mortality states 89 and exposure to Agent Orange among veterans 90 were found to be associated with an increased risk of ADRD. Additionally, lithium levels in drinking water were associated with greater risk of dementia in women. 91 DISCUSSION In this scoping review, we conducted comprehensive searches across three major databases to identify studies that utilized EHR data to analyze risk factors associated with cognitive decline. The final selection of 80 articles spans a wide range of risk factors, including medical conditions, interventions, lifestyle, socioeconomic status, psychosocial, and environmental factors. The majority of studied medical conditions were associated with an elevated risk of ADRD, whereas medical interventions addressing these conditions often reduced the ADRD risk. Using large and diverse EHR datasets has enriched the literature on antecedent risk factors for dementia and confirmed findings from smaller sample studies. Longitudinal EHR data are essential for ADRD research due to the slow progression of the disease. The prolonged latency period between risk factor exposure and clinical symptoms necessitates extended observation to identify early signs and risk factors, facilitating causality assessment. Utilizing EHR datasets offers numerous benefits for ADRD research. These datasets provide extensive data with a wealth of variables, enabling the exploration of diverse medical conditions and interventions to identify risk and protective factors for cognitive impairment and dementia. These datasets allow simultaneously investigation of multiple potential risk and protective factors while enabling comprehensive adjustments for confounders. Access to large and diverse EHR datasets enhances statistical power, 92 allowing for the study of rare events and the identification of unique risk profiles and disease trajectories. 59 , 90 These datasets encompass individuals from various backgrounds, facilitating research across different populations and the examination of various disease subtypes and clinical presentation variations. EHR offers rich, detailed clinical data that enable in-depth studies into the clinical aspects and mechanisms of ADRD. Additionally, EHR datasets can confirm and provide unique insights into factors sometimes overlooked or absent in other types of studies. To facilitate the investigation of risk factors, including socioeconomic aspects, lifestyle, and environmental factors, EHR data are often linked to external datasets using patient identifiers like names, social security numbers, and zip codes. This approach enables the exploration of additional factors and the incorporation of confounding variables from the EHR. The utilization of EHR data has the potential to help identify new risk factors for ADRD, as well as analyze the traditionally recognized risk factors from a new perspective. Traditional risk factors, such as diabetes, 23 , 26 , 35 , 60 , 61 hypertension, 23 , 61 , 63 , 64 stroke, 23 hyperlipidemia, 23 and traumatic brain injury, 74 have been confirmed in the studies utilizing EHR data. Additionally, our review presents a list of newly recognized potential risk factors emerging from EHR data analysis. These include but are not limited to, environmental exposures like Agent Orange, 90 infections such as COVID-19, 29 and certain surgical procedures previously not associated with ADRD risk. The study by Kim et al, 79 for example, was the first to find that bariatric surgery increases the risk of ADRD, which contrasts with earlier research that has suggested potential cognitive benefits related to weight loss and metabolic improvement post-surgery. The advent of big data has enabled the identification of these novel risk factors, offering fresh insights into the multifactorial nature of ADRD. Exploring various populations and EHR datasets reveals inconsistencies in findings on factors like obesity, hypertension, visual impairment, metformin, and underweight, as well as potential conflicts with results from studies not included in this review. The divergent findings underscore the complexity of ADRD risk factors, emphasizing the importance of further research to elucidate these relationships. Using EHR datasets for ADRD research offers valuable insights but comes with notable limitations. The accuracy and completeness of diagnostic coding in EHRs can vary, impacting the reliability of outcome and exposure classification. Another constraint is the outcome measure heterogeneity and quality in EHR-based studies. Dementia definitions vary, including or excluding subtypes like vascular dementia and LBD, and using different coding systems (ICD, SNOMED CT, READ). Some use cognitive tests with smaller samples, while others rely on ICD codes for larger samples but potentially less specific diagnoses. This diversity in dementia definitions reflects the complexity of diagnosing and classifying cognitive decline and dementia in real-world clinical settings. It affects the identification of cognitive decline risk factors, leading to variability in reported associations. For instance, studies focusing on specific dementia subtypes may reveal unique risk factors that differ from those identified in broader dementia studies. The choice of diagnostic codes and cognitive assessments can also influence the accuracy of dementia identification, thereby affecting the strength and direction of associations between risk factors and cognitive decline. Minimizing variability in outcome measures could substantially enhance the interpretability and comparability of findings in cognitive decline research. Standardizing the criteria for dementia diagnosis across majority of healthcare providers, as opposed to limiting it to a few specialists (dementia experts), could simplify the synthesis of research results and refine the accuracy of associations with risk factor. It could also enhance the detection of subtle or nuanced associations between risk factors and cognitive decline that might be obscured by the current heterogeneity. EHR-based studies provide valuable insights but do not conclusively establish causality due to the potential influence of uncontrolled confounding variables. Investigations into the link between depression and dementia highlight this challenge. Studies related to diabetes management often fail to distinguish between the cognitive effects of specific diabetes medications and those resulting from overall glycemic control, leaving it unclear if observed benefits stem from particular drugs or general blood sugar management. Additionally, trazodone was found as a risk factor for ADRD; however, the study suggests that the higher incidence of dementia observed among trazodone users might not imply a direct causal relationship but could instead reflect the medication's use in managing symptoms common in the early stages of cognitive impairment. 54 Therefore, when interpreting results from those included observational studies, readers should be cautious not to presume a direct causal relationship between the risk factors studied and the outcomes. Furthermore, the inherent biases in observational studies, including potential confounding, selection bias, and information bias, continue to be pervasive issues. Although most included studies attempted to adjust for known confounders, the possibility of residual confounding cannot be dismissed. Adjusting for confounders in survival models may not be sufficient, especially with numerous confounders or significant covariate overlap between the groups being compared. This can lead to issues such as multicollinearity and overfitting. Advanced statistical methods, including propensity score matching (PSM) and inverse probability weighting (IPW), are often used to reduce bias in the estimation of exposure or treatment effects. Nevertheless, EHR-based studies are not equivalent to randomized controlled clinical trials, the gold standard for establishing causality. Researchers should also consider the context of EHR data collection, including demographic and clinical characteristics of study populations. Variations in healthcare access and utilization across different populations could influence the observed associations. Notably, crucial data, such as information on deaths, may be absent from the EHRs. While some studies have cross-referenced EHR data with external databases to create more comprehensive datasets, not all have followed this approach. Additional methodological concerns arise in statistical analysis of the included studies. Long follow-up times introduce competing events like death, potentially impacting the event of interest (e.g., AD diagnosis). The widely used Cox model is not suitable for handling competing risks properly, as it treats them as censored, potentially yielding biased results when the assumption of independent censoring is violated. In contrast, the Fine-Gray model estimates covariate effects on the sub-distribution hazard, offering insights into risk and protective factors' relationships with the event of interest while considering competing risks. Therefore, it is crucial to evaluate study-specific quality indicators, like adherence to the STROBE guidelines, validated outcome measures, and statistical analyses robustness, to prevent overinterpretation of the findings. Lastly, geographic and demographic constraints exist. Despite the extensive data in EHR systems, research is often localized to specific healthcare systems or geographic locales, limiting generalizability. For instance, unlike UK, the US and other countries appear to underutilize national-level EHR datasets. Despite assess to longitudinal EHR datasets across various healthcare systems and regions, research is often confined to specific EHRs. The VHA dataset, though national, predominantly represent male individuals, poses a demographic limitation. Expanding the use of such comprehensive data sources can provide a more representative sample and enhance research generalizability. The lack of research utilizing large, diverse, national EHR datasets underscore the need for future studies on dementia risk through such resources. The underdiagnosis of MCI and dementia presents a significant challenge in ADRD research, particularly during early stages. Reliance on EHRs for diagnosis can inadvertently contribute to underreporting, affecting the accuracy of prevalence and incidence rates in the literature. This skewing, due to EHR-based data extraction, might underestimate the true burden of these conditions. Consequently, such underestimation can impact systematic or scoping review findings, altering our understanding of risk factors, disease progression, and intervention effectiveness. Interestingly, individuals frequently interacting with psychiatric services for other conditions are more likely to have cognitive impairment noted in their EHRs compared to those without psychiatric conditions. Therefore, studies that consider psychiatric conditions as risk factors for ADRD particularly require careful interpretation. Future directions The analysis of the articles suggests several avenues for future investigation using EHR data. Medical interventions: The impact of medical treatments on reducing cognitive decline in the context of various medical conditions remains unclear. There is a lack of research on pharmacological and surgical effects compared to studies on medical conditions and ADRD. Future research should prioritize studying the relationship between medical interventions and cognitive decline more broadly. Explore overlooked factors: investigate additional risk or protective factors, like genetic markers (e.g., apolipoprotein E, presenilin 1 and 2, and amyloid precursor protein), environmental toxins (e.g., lead, pesticides), 93 mild traumatic brain injury, 94 endocrine factors (such as hypothyroidism), sleep disturbance (like sleep apnea or chronic sleep deprivation), 7 , 95 bilingualism, 96 vitamin and nutritional deficiencies, 97 and the microbiome (e.g., gut microbiome). 98 Clinical notes and AI: Almost all the reviewed articles have used data from structured fields of the EHR. Certain conditions and symptoms (e.g., hearing loss, sleep disturbances) that are not consistently captured in structured EHR data may require the examination of clinical notes to identify them, often necessitating AI and natural language processing. Early cognitive decline: While the existing literature primary focuses on dementia or AD, fewer studies address the early onset of AD and the initial stages of cognitive decline, such as mild cognitive impairment and subjective cognitive decline. Diversify study populations: Most EHR-based studies have focused on populations with well-defined medical conditions like diabetes, hypertension, cancer, and HIV. To advance research, it’s essential to include a broader range of specific groups, such as sexual and gender minorities, 99 , 100 indigenous populations, those resilient to cognitive decline, and various psychiatric cohorts. Database integration: Integrating diverse EHR database across institutions and locations, like the UK’s national datasets, can expand study populations and enhance research generalizability, which is currently underutilized in the US and other countries. Data linkage: EHRs lack some data and require linkage with other datasets, 101 including insurance claims, genetics, socioeconomic status, 102 lifestyle, crime, and environmental factors (e.g., air pollution, wildfires, climate change, toxic chemicals). Limitations This review has several limitations to acknowledge. First, our search was constrained to three databases, potentially missing relevant studies in other sources. Second, our search term, focused on titles and abstracts, might have overlooked articles using different terminology or mentioning EHR components (e.g., clinical notes) in the methods section. Third, we didn’t perform a bias assessment for included observational studies, which is important considering biases in EHR data collection and outcome measures. Fourth, this review doesn’t aim to provide a comprehensive overview of ADRD risk factors; instead, it focuses on what has been studied using EHR data. Finally, we refrained from conducting a meta-analysis due to variations in adjusted confounders among studies, complicating cross-study comparisons. CONCLUSION EHR data, with its rich and diverse longitudinal real-world information, provides substantial insights into the medical conditions, interventions, lifestyle, socioeconomic, and environmental factors associated with ADRD risk. Looking ahead, research should focus on diversifying study populations and integrating EHR data across geographical locations and with non-EHR datasets. There is also a need to enhance the extraction of information from unstructured text to explore a broader range of risk factors for ADRD. Abbreviations electronic health records (EHR), Alzheimer's disease (AD), mild cognitive impairment (MCI), Alzheimer's disease and related dementias (ADRD), Strengthening the Reporting of Observational Studies in Epidemiology (STROBE), Veterans Health Administration (VHA), Lewy body dementia (LBD), frontotemporal dementia (FTD), symptomatic Herpes Simplex Virus 1 (HSV-1), Herpes Zoster (HZ), Short Physical Performance Battery (SPPB), nonsteroidal anti-inflammatory drugs (NSAIDs), selective serotonin reuptake inhibitor (SSRI), propensity score matching (PSM), inverse probability weighting (IPW) Declarations Ethics approval and consent to participate: Not applicable Consent for publication: Not applicable Availability of data and materials: This article is a literature review and does not involve the generation of new data. All data and materials used in this review are derived from publicly available sources and previously published literature. References to these sources are provided within the manuscript. Authors' contributions: Conceptualization: Wang, Yang Data curation: Wang, Yang, Sha, Kuraszkiewicz, Leonik Formal analysis: Wang, Yang, Sha, Leonik, Marshall Investigation: All authors Methodology: Wang, Yang Project administration: Wang, Yang Supervision: Wang, Zhou, Marshall Roles/Writing - original draft: Wang, Yang Writing - review & editing: All authors Funding acquisition: Wang Resources: Wang, Zhou Competing interests : Authors have nothing to disclose. Funding : LW and RY are supported by the National Institutes of Health grants K99AG075190 and Alzheimer’s Association Research Fellowship grant AARF-22-924992. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Acknowledgements: Not applicable Declaration of Generative AI and AI-assisted technologies in the writing process During the preparation of this work the authors used GPT-4 in order to improve the readability and language. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication. References Jack Jr CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimer's & Dementia 2018; 14: 535-562. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia 2011; 7: 280-292. Association As. 2023 Alzheimer's disease facts and figures. Alzheimer's & dementia 2023; 19. DOI: 10.1002/alz.13016. Veitch DP, Weiner MW, Aisen PS, et al. Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. Alzheimers Dement 2022; 18: 824-857. 2021/09/29. DOI: 10.1002/alz.12422. Dagley A, LaPoint M, Huijbers W, et al. Harvard aging brain study: dataset and accessibility. Neuroimage 2017; 144: 255-258. Wolters FJ, Segufa RA, Darweesh SKL, et al. Coronary heart disease, heart failure, and the risk of dementia: A systematic review and meta-analysis. Alzheimers Dement 2018; 14: 1493-1504. 2018/03/02. DOI: 10.1016/j.jalz.2018.01.007. Shi L, Chen SJ, Ma MY, et al. Sleep disturbances increase the risk of dementia: A systematic review and meta-analysis. Sleep Med Rev 2018; 40: 4-16. 2017/09/12. DOI: 10.1016/j.smrv.2017.06.010. Kuiper JS, Zuidersma M, Oude Voshaar RC, et al. Social relationships and risk of dementia: A systematic review and meta-analysis of longitudinal cohort studies. Ageing Res Rev 2015; 22: 39-57. 2015/05/10. DOI: 10.1016/j.arr.2015.04.006. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. International journal of surgery 2021; 88: 105906. Knottnerus A and Tugwell P. STROBE--a checklist to Strengthen the Reporting of Observational Studies in Epidemiology. J Clin Epidemiol 2008; 61: 323. 2008/03/04. DOI: 10.1016/j.jclinepi.2007.11.006. Cox DR. Regression models and life‐tables. Journal of the Royal Statistical Society: Series B (Methodological) 1972; 34: 187-202. Fine JP and Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the American statistical association 1999; 94: 496-509. Ford AH, Yeap BB, Flicker L, et al. Sex hormones and incident dementia in older men: The health in men study. Psychoneuroendocrinology 2018; 98: 139-147. 2018/08/26. DOI: 10.1016/j.psyneuen.2018.08.013. Almeida OP, Hankey GJ, Yeap BB, et al. Depression as a risk factor for cognitive impairment in later life: the Health In Men cohort study. Int J Geriatr Psychiatry 2016; 31: 412-420. 2015/08/19. DOI: 10.1002/gps.4347. Almeida OP, Ford AH, Hankey GJ, et al. Risk of dementia associated with psychotic disorders in later life: the health in men study (HIMS). Psychol Med 2019; 49: 232-242. 2018/03/23. DOI: 10.1017/s003329171800065x. Lee CH, Lui DTW, Cheung CYY, et al. Different glycaemia-related risk factors for incident Alzheimer's disease in men and women with type 2 diabetes-A sex-specific analysis of the Hong Kong diabetes database. Diabetes Metab Res Rev 2021; 37: e3401. 2020/09/02. DOI: 10.1002/dmrr.3401. Hsu WWQ, Zhang X, Sing CW, et al. Hip Fracture as a Predictive Marker for the Risk of Dementia: A Population-Based Cohort Study. J Am Med Dir Assoc 2022; 23: 1720 e1721-1720 e1729. 2022/08/22. DOI: 10.1016/j.jamda.2022.07.013. Cui S, Fang F, Cui P, et al. Associations between the use of beta-adrenoceptor acting drugs and the risk of dementia in older population. Front Neurol 2022; 13: 999666. 2023/01/10. DOI: 10.3389/fneur.2022.999666. Schnier C, Janbek J, Williams L, et al. Antiherpetic medication and incident dementia: Observational cohort studies in four countries. Eur J Neurol 2021; 28: 1840-1848. 2021/03/04. DOI: 10.1111/ene.14795. Perera G, Rijnbeek PR, Alexander M, et al. Vascular and metabolic risk factor differences prior to dementia diagnosis: a multidatabase case-control study using European electronic health records. BMJ Open 2020; 10: e038753. 2020/11/17. DOI: 10.1136/bmjopen-2020-038753. Newby D, Prieto-Alhambra D, Duarte-Salles T, et al. Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study. Alzheimers Res Ther 2020; 12: 38. 2020/04/08. DOI: 10.1186/s13195-020-00606-5. Hafdi M, Hoevenaar-Blom MP, Beishuizen CRL, et al. Association of Benzodiazepine and Anticholinergic Drug Usage With Incident Dementia: A Prospective Cohort Study of Community-Dwelling Older Adults. J Am Med Dir Assoc 2020; 21: 188-193.e183. 2019/07/14. DOI: 10.1016/j.jamda.2019.05.010. Kuo SC, Lai SW, Hung HC, et al. Association between comorbidities and dementia in diabetes mellitus patients: population-based retrospective cohort study. J Diabetes Complications 2015; 29: 1071-1076. 2015/08/04. DOI: 10.1016/j.jdiacomp.2015.06.010. Liu CH, Sung PS, Li YR, et al. Telmisartan use and risk of dementia in type 2 diabetes patients with hypertension: A population-based cohort study. PLoS Med 2021; 18: e1003707. 2021/07/20. DOI: 10.1371/journal.pmed.1003707. Papadopoulos E, Abu Helal A, Berger A, et al. Objective measures of physical function and their association with cognitive impairment in older adults with cancer prior to treatment. J Geriatr Oncol 2022; 13: 1141-1148. 2022/07/26. DOI: 10.1016/j.jgo.2022.07.007. Pham ANQ, Lindeman C, Voaklander D, et al. Risk factors for incidence of dementia in primary care practice: a retrospective cohort study in older adults. Fam Pract 2022; 39: 406-412. 2021/12/16. DOI: 10.1093/fampra/cmab168. Halliday A, Sneade M, Björck M, et al. Editor's Choice - Effect of Carotid Endarterectomy on 20 Year Incidence of Recorded Dementia: A Randomised Trial. Eur J Vasc Endovasc Surg 2022; 63: 535-545. 2022/03/12. DOI: 10.1016/j.ejvs.2021.12.041. Kivimäki M, Singh-Manoux A, Batty GD, et al. Association of Alcohol-Induced Loss of Consciousness and Overall Alcohol Consumption With Risk for Dementia. JAMA Netw Open 2020; 3: e2016084. 2020/09/10. DOI: 10.1001/jamanetworkopen.2020.16084. Wang L, Davis PB, Volkow ND, et al. Association of COVID-19 with New-Onset Alzheimer's Disease. J Alzheimers Dis 2022; 89: 411-414. 2022/08/02. DOI: 10.3233/jad-220717. Gorenflo MP, Davis PB, Kendall EK, et al. Association of Aspirin Use with Reduced Risk of Developing Alzheimer's Disease in Elderly Ischemic Stroke Patients: A Retrospective Cohort Study. J Alzheimers Dis 2023; 91: 697-704. 2022/12/12. DOI: 10.3233/jad-220901. Proietti R, Rivera-Caravaca JM, López-Gálvez R, et al. Cerebrovascular, Cognitive and Cardiac Benefits of SGLT2 Inhibitors Therapy in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus: Results from a Global Federated Health Network Analysis. J Clin Med 2023; 12 2023/04/28. DOI: 10.3390/jcm12082814. Aggarwal M, Alkhayyat M, Abou Saleh M, et al. Alzheimer Disease Occurs More Frequently In Patients With Inflammatory Bowel Disease: Insight From a Nationwide Study. J Clin Gastroenterol 2023; 57: 501-507. 2022/04/27. DOI: 10.1097/mcg.0000000000001714. Newby D, Linden AB, Fernandes M, et al. Comparative effect of metformin versus sulfonylureas with dementia and Parkinson's disease risk in US patients over 50 with type 2 diabetes mellitus. BMJ Open Diabetes Res Care 2022; 10 2022/09/16. DOI: 10.1136/bmjdrc-2022-003036. Lindbohm JV, Mars N, Walker KA, et al. Plasma proteins, cognitive decline, and 20-year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies. Alzheimers Dement 2022; 18: 612-624. 2021/08/03. DOI: 10.1002/alz.12419. Barbiellini Amidei C, Fayosse A, Dumurgier J, et al. Association Between Age at Diabetes Onset and Subsequent Risk of Dementia. Jama 2021; 325: 1640-1649. 2021/04/28. DOI: 10.1001/jama.2021.4001. Singh-Manoux A, Oumarou-Ibrahim A, Machado-Fragua MD, et al. Association between kidney function and incidence of dementia: 10-year follow-up of the Whitehall II cohort study. Age Ageing 2022; 51 2022/01/22. DOI: 10.1093/ageing/afab259. Akbaraly TN, Singh-Manoux A, Dugravot A, et al. Association of Midlife Diet With Subsequent Risk for Dementia. Jama 2019; 321: 957-968. 2019/03/13. DOI: 10.1001/jama.2019.1432. Rusmaully J, Dugravot A, Moatti JP, et al. Contribution of cognitive performance and cognitive decline to associations between socioeconomic factors and dementia: A cohort study. PLoS Med 2017; 14: e1002334. 2017/06/27. DOI: 10.1371/journal.pmed.1002334. Sommerlad A, Sabia S, Singh-Manoux A, et al. Association of social contact with dementia and cognition: 28-year follow-up of the Whitehall II cohort study. PLoS Med 2019; 16: e1002862. 2019/08/03. DOI: 10.1371/journal.pmed.1002862. Cao Z, Xu C, Yang H, et al. Associations of BMI and Serum Urate with Developing Dementia: A Prospective Cohort Study. J Clin Endocrinol Metab 2020; 105 2020/09/13. DOI: 10.1210/clinem/dgaa638. Littlejohns TJ, Hayat S, Luben R, et al. Visual Impairment and Risk of Dementia in 2 Population-Based Prospective Cohorts: UK Biobank and EPIC-Norfolk. J Gerontol A Biol Sci Med Sci 2022; 77: 697-704. 2021/11/01. DOI: 10.1093/gerona/glab325. Muzambi R, Bhaskaran K, Rentsch CT, et al. Are infections associated with cognitive decline and neuroimaging outcomes? A historical cohort study using data from the UK Biobank study linked to electronic health records. Transl Psychiatry 2022; 12: 385. 2022/09/16. DOI: 10.1038/s41398-022-02145-z. Geng T, Lu Q, Wan Z, et al. Association of serum 25-hydroxyvitamin D concentrations with risk of dementia among individuals with type 2 diabetes: A cohort study in the UK Biobank. PLoS Med 2022; 19: e1003906. 2022/01/14. DOI: 10.1371/journal.pmed.1003906. Wang B, Wang N, Sun Y, et al. Association of Combined Healthy Lifestyle Factors With Incident Dementia in Patients With Type 2 Diabetes. Neurology 2022; 99: e2336-e2345. 2022/09/15. DOI: 10.1212/wnl.0000000000201231. Khondoker M, Macgregor A, Bachmann MO, et al. Multimorbidity pattern and risk of dementia in later life: an 11-year follow-up study using a large community cohort and linked electronic health records. J Epidemiol Community Health 2023; 77: 285-292. 2023/03/09. DOI: 10.1136/jech-2022-220034. Elovainio M, Lahti J, Pirinen M, et al. Association of social isolation, loneliness and genetic risk with incidence of dementia: UK Biobank Cohort Study. BMJ Open 2022; 12: e053936. 2022/02/25. DOI: 10.1136/bmjopen-2021-053936. Herbert A, Wijlaars L, Zylbersztejn A, et al. Data resource profile: hospital episode statistics admitted patient care (HES APC). International journal of epidemiology 2017; 46: 1093-1093i. Harley K and Jones C. Quality of Scottish morbidity record (SMR) data. Health bulletin 1996; 54: 410-417. Mehta HB, Mehta V and Goodwin JS. Association of Hypoglycemia With Subsequent Dementia in Older Patients With Type 2 Diabetes Mellitus. J Gerontol A Biol Sci Med Sci 2017; 72: 1110-1116. 2016/10/28. DOI: 10.1093/gerona/glw217. Warren-Gash C, Williamson E, Shiekh SI, et al. No evidence that herpes zoster is associated with increased risk of dementia diagnosis. Ann Clin Transl Neurol 2022; 9: 363-374. 2022/02/17. DOI: 10.1002/acn3.51525. Dregan A, Chowienczyk P and Armstrong D. Patterns of anti-inflammatory drug use and risk of dementia: a matched case-control study. Eur J Neurol 2015; 22: 1421-1428. 2015/07/16. DOI: 10.1111/ene.12774. Cadogan SL, Powell E, Wing K, et al. Anticoagulant prescribing for atrial fibrillation and risk of incident dementia. Heart 2021; 107: 1898-1904. 2021/10/15. DOI: 10.1136/heartjnl-2021-319672. Floud S, Simpson RF, Balkwill A, et al. Body mass index, diet, physical inactivity, and the incidence of dementia in 1 million UK women. Neurology 2020; 94: e123-e132. 2019/12/20. DOI: 10.1212/WNL.0000000000008779. Brauer R, Lau WCY, Hayes JF, et al. Trazodone use and risk of dementia: A population-based cohort study. PLoS Med 2019; 16: e1002728. 2019/02/06. DOI: 10.1371/journal.pmed.1002728. Lu N, Dubreuil M, Zhang Y, et al. Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study. Ann Rheum Dis 2016; 75: 547-551. 2015/03/06. DOI: 10.1136/annrheumdis-2014-206917. Hendrie HC, Zheng M, Li W, et al. Glucose level decline precedes dementia in elderly African Americans with diabetes. Alzheimers Dement 2017; 13: 111-118. 2016/10/30. DOI: 10.1016/j.jalz.2016.08.017. Lee CS, Gibbons LE, Lee AY, et al. Association Between Cataract Extraction and Development of Dementia. JAMA Intern Med 2022; 182: 134-141. 2021/12/07. DOI: 10.1001/jamainternmed.2021.6990. Lee CS, Lee ML, Gibbons LE, et al. Associations Between Retinal Artery/Vein Occlusions and Risk of Vascular Dementia. J Alzheimers Dis 2021; 81: 245-253. 2021/03/23. DOI: 10.3233/jad-201492. Ibler E, Tran G, Orrell KA, et al. Inverse association for diagnosis of Alzheimer's disease subsequent to both melanoma and non-melanoma skin cancers in a large, urban, single-centre, Midwestern US patient population. J Eur Acad Dermatol Venereol 2018; 32: 1893-1896. 2018/03/25. DOI: 10.1111/jdv.14952. Doney ASF, Bonney W, Jefferson E, et al. Investigating the Relationship Between Type 2 Diabetes and Dementia Using Electronic Medical Records in the GoDARTS Bioresource. Diabetes Care 2019; 42: 1973-1980. 2019/08/09. DOI: 10.2337/dc19-0380. Nagar SD, Pemu P, Qian J, et al. Investigation of hypertension and type 2 diabetes as risk factors for dementia in the All of Us cohort. Sci Rep 2022; 12: 19797. 2022/11/18. DOI: 10.1038/s41598-022-23353-z. Hendrie HC, Zheng M, Lane KA, et al. Changes of glucose levels precede dementia in African-Americans with diabetes but not in Caucasians. Alzheimers Dement 2018; 14: 1572-1579. 2018/04/22. DOI: 10.1016/j.jalz.2018.03.008. Gilsanz P, Mayeda ER, Glymour MM, et al. Female sex, early-onset hypertension, and risk of dementia. Neurology 2017; 89: 1886-1893. 2017/10/06. DOI: 10.1212/wnl.0000000000004602. Abell JG, Kivimäki M, Dugravot A, et al. Association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension. Eur Heart J 2018; 39: 3119-3125. 2018/06/15. DOI: 10.1093/eurheartj/ehy288. Whiteley WN, Gupta AK, Godec T, et al. Long-Term Incidence of Stroke and Dementia in ASCOT. Stroke 2021; 52: 3088-3096. 2021/07/02. DOI: 10.1161/strokeaha.120.033489. Bobrow K, Xia F, Hoang T, et al. HIV and risk of dementia in older veterans. Aids 2020; 34: 1673-1679. 2020/07/24. DOI: 10.1097/qad.0000000000002597. Lam JO, Hou CE, Hojilla JC, et al. Comparison of dementia risk after age 50 between individuals with and without HIV infection. AIDS 2021; 35: 821-828. 2021/01/05. DOI: 10.1097/QAD.0000000000002806. Katz J and Gao H. The Alzheimer-E. coli Axis: What Can We Learn from an Electronic Health Record Platform. J Alzheimers Dis 2021; 84: 717-721. 2021/09/28. DOI: 10.3233/jad-215004. Young-Xu Y, Powell EI, Zwain GM, et al. Symptomatic Herpes Simplex Virus Infection and Risk of Dementia in US Veterans: a Cohort Study. Neurotherapeutics 2021; 18: 2458-2467. 2021/07/11. DOI: 10.1007/s13311-021-01084-9. Gilsanz P, Schnaider Beeri M, Karter AJ, et al. Depression in type 1 diabetes and risk of dementia. Aging Ment Health 2019; 23: 880-886. 2018/04/11. DOI: 10.1080/13607863.2018.1455167. Chan AX, Bakhoum CY, Bangen KJ, et al. Relationship between Retinal Vascular Occlusions and Cognitive Dementia in a Large Cross-Sectional Cohort. Am J Ophthalmol 2021; 226: 201-205. 2021/02/03. DOI: 10.1016/j.ajo.2021.01.026. Exalto LG, Biessels GJ, Karter AJ, et al. Severe diabetic retinal disease and dementia risk in type 2 diabetes. J Alzheimers Dis 2014; 42 Suppl 3: S109-117. 2014/03/15. DOI: 10.3233/jad-132570. Rodill LG, Exalto LG, Gilsanz P, et al. Diabetic Retinopathy and Dementia in Type 1 Diabetes. Alzheimer Dis Assoc Disord 2018; 32: 125-130. 2017/12/21. DOI: 10.1097/wad.0000000000000230. Barnes DE, Kaup A, Kirby KA, et al. Traumatic brain injury and risk of dementia in older veterans. Neurology 2014; 83: 312-319. 2014/06/27. DOI: 10.1212/wnl.0000000000000616. Kim Y, Lhatoo S, Zhang GQ, et al. Temporal phenotyping for transitional disease progress: An application to epilepsy and Alzheimer's disease. J Biomed Inform 2020; 107: 103462. 2020/06/21. DOI: 10.1016/j.jbi.2020.103462. Xu J, Wang F, Zang C, et al. Comparing the effects of four common drug classes on the progression of mild cognitive impairment to dementia using electronic health records. Sci Rep 2023; 13: 8102. 2023/05/20. DOI: 10.1038/s41598-023-35258-6. Salas J, Morley JE, Scherrer JF, et al. Risk of incident dementia following metformin initiation compared with noninitiation or delay of antidiabetic medication therapy. Pharmacoepidemiol Drug Saf 2020; 29: 623-634. 2020/05/05. DOI: 10.1002/pds.5014. Tang X, Brinton RD, Chen Z, et al. Use of oral diabetes medications and the risk of incident dementia in US veterans aged ≥60 years with type 2 diabetes. BMJ Open Diabetes Res Care 2022; 10 2022/10/12. DOI: 10.1136/bmjdrc-2022-002894. Kim J, Kelley J, Kleinschmit K, et al. Development of dementia in patients who underwent bariatric surgery. Surg Endosc 2023; 37: 3507-3521. 2022/12/30. DOI: 10.1007/s00464-022-09837-z. Zhou M, Xu R, Kaelber DC, et al. Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer's disease in patients with rheumatoid arthritis and psoriasis. PLoS One 2020; 15: e0229819. 2020/03/24. DOI: 10.1371/journal.pone.0229819. Wang C, Gao S, Hendrie HC, et al. Antidepressant Use in the Elderly Is Associated With an Increased Risk of Dementia. Alzheimer Dis Assoc Disord 2016; 30: 99-104. 2015/08/22. DOI: 10.1097/wad.0000000000000103. Nead KT, Gaskin G, Chester C, et al. Androgen Deprivation Therapy and Future Alzheimer's Disease Risk. J Clin Oncol 2016; 34: 566-571. 2015/12/09. DOI: 10.1200/jco.2015.63.6266. Nead KT, Gaskin G, Chester C, et al. Association Between Androgen Deprivation Therapy and Risk of Dementia. JAMA Oncol 2017; 3: 49-55. 2016/10/14. DOI: 10.1001/jamaoncol.2016.3662. Bromley SE, Matthews A, Smeeth L, et al. Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK. J Cancer Surviv 2019; 13: 632-640. 2019/07/20. DOI: 10.1007/s11764-019-00782-w. Flores AC, Jensen GL, Mitchell DC, et al. Prospective Study of Diet Quality and the Risk of Dementia in the Oldest Old. Nutrients 2023; 15 2023/03/12. DOI: 10.3390/nu15051282. Soh Y, Whitmer RA, Mayeda ER, et al. State-Level Indicators of Childhood Educational Quality and Incident Dementia in Older Black and White Adults. JAMA Neurol 2023; 80: 352-359. 2023/02/14. DOI: 10.1001/jamaneurol.2022.5337. Hayes-Larson E, Ikesu R, Fong J, et al. Association of Education With Dementia Incidence Stratified by Ethnicity and Nativity in a Cohort of Older Asian American Individuals. JAMA Netw Open 2023; 6: e231661. 2023/03/07. DOI: 10.1001/jamanetworkopen.2023.1661. Becerril A, Pfoh ER, Hashmi AZ, et al. Racial, ethnic and neighborhood socioeconomic differences in incidence of dementia: A regional retrospective cohort study. J Am Geriatr Soc 2023 2023/03/18. DOI: 10.1111/jgs.18322. Gilsanz P, Mayeda ER, Glymour MM, et al. Association Between Birth in a High Stroke Mortality State, Race, and Risk of Dementia. JAMA Neurol 2017; 74: 1056-1062. 2017/08/02. DOI: 10.1001/jamaneurol.2017.1553. Martinez S, Yaffe K, Li Y, et al. Agent Orange Exposure and Dementia Diagnosis in US Veterans of the Vietnam Era. JAMA Neurol 2021; 78: 473-477. 2021/01/26. DOI: 10.1001/jamaneurol.2020.5011. Duthie AC, Hannah J, Batty GD, et al. Low-level lithium in drinking water and subsequent risk of dementia: Cohort study. Int J Geriatr Psychiatry 2023; 38: e5890. 2023/02/08. DOI: 10.1002/gps.5890. Casey JA, Schwartz BS, Stewart WF, et al. Using Electronic Health Records for Population Health Research: A Review of Methods and Applications. Annu Rev Public Health 2016; 37: 61-81. 2015/12/17. DOI: 10.1146/annurev-publhealth-032315-021353. Yan D, Zhang Y, Liu L, et al. Pesticide exposure and risk of Alzheimer's disease: a systematic review and meta-analysis. Sci Rep 2016; 6: 32222. 2016/09/02. DOI: 10.1038/srep32222. Clark E, Faruque S, Mutebi C, et al. Investigating the relationship between mild traumatic brain injury and Alzheimer's disease and related dementias: a systematic review. J Neurol 2022; 269: 4635-4645. 2022/06/02. DOI: 10.1007/s00415-022-11186-9. Guay-Gagnon M, Vat S, Forget MF, et al. Sleep apnea and the risk of dementia: A systematic review and meta-analysis. J Sleep Res 2022; 31: e13589. 2022/04/03. DOI: 10.1111/jsr.13589. Brini S, Sohrabi HR, Hebert JJ, et al. Bilingualism Is Associated with a Delayed Onset of Dementia but Not with a Lower Risk of Developing it: a Systematic Review with Meta-Analyses. Neuropsychol Rev 2020; 30: 1-24. 2020/02/10. DOI: 10.1007/s11065-020-09426-8. Zhou J, Sun Y, Ji M, et al. Association of Vitamin B Status with Risk of Dementia in Cohort Studies: A Systematic Review and Meta-Analysis. J Am Med Dir Assoc 2022; 23: 1826 e1821-1826 e1835. 2022/07/03. DOI: 10.1016/j.jamda.2022.05.022. Coradduzza D, Sedda S, Cruciani S, et al. Age-Related Cognitive Decline, Focus on Microbiome: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences 2023; 24: 13680. Hua Y, Wang L, Nguyen V, et al. A deep learning approach for transgender and gender diverse patient identification in electronic health records. J Biomed Inform 2023; 147: 104507. 2023/10/02. DOI: 10.1016/j.jbi.2023.104507. Romanelli RJ, Rosenblatt AS, Marcum ZA, et al. Cognitive Impairment in Sexual and Gender Minority Groups: A Scoping Review of the Literature. LGBT Health 2023 2023/10/12. DOI: 10.1089/lgbt.2023.0095. DeBord DG, Carreon T, Lentz TJ, et al. Use of the "Exposome" in the Practice of Epidemiology: A Primer on -Omic Technologies. Am J Epidemiol 2016; 184: 302-314. 2016/08/16. DOI: 10.1093/aje/kwv325. Kind AJH and Buckingham WR. Making Neighborhood-Disadvantage Metrics Accessible - The Neighborhood Atlas. N Engl J Med 2018; 378: 2456-2458. 2018/06/28. DOI: 10.1056/NEJMp1802313. Biondo F, Jewell A, Pritchard M, et al. Brain-age is associated with progression to dementia in memory clinic patients. Neuroimage Clin 2022; 36: 103175. 2022/09/11. DOI: 10.1016/j.nicl.2022.103175. Russ TC, Hannah J, Batty GD, et al. Childhood Cognitive Ability and Incident Dementia: The 1932 Scottish Mental Survey Cohort into their 10th Decade. Epidemiology 2017; 28: 361-364. 2017/02/06. DOI: 10.1097/ede.0000000000000626. Schulte PJ, Warner DO, Martin DP, et al. Association Between Critical Care Admissions and Cognitive Trajectories in Older Adults. Crit Care Med 2019; 47: 1116-1124. 2019/05/21. DOI: 10.1097/ccm.0000000000003829. Additional Declarations No competing interests reported. Supplementary Files Supplementarytables.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4671544","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":334381865,"identity":"11d410e3-54a7-4bb3-85d9-50b39e1dd6a5","order_by":0,"name":"Liqin Wang","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA6UlEQVRIiWNgGAWjYBACPjBZcYDBgIEHKnSAgUECnxY2MHmGZC2MbSRpkUh+9vDrvDuJ2xl4D36ubLPL5zvAfPA2D14taebGstueJe5s4EuWPNuWbDnzAFuyNV4t0glm0pLbDuduOMBjINlwhtnA4ACPmTR+LenfpCXngLUY/2w4Uw/Uwv+NgJYcM8mPDWAtZpINFYdBtrDh1yL/pkya4diz+g2HecwsGyqOG0geZjO2nINHCz/P8W2SP2ruGBsc7zG+2WBQbcB3vPnhjTd4tIAAM9gZzHAuAeUgwPiDCEWjYBSMglEwggEA2ydMnsAVJQ4AAAAASUVORK5CYII=","orcid":"","institution":"Brigham and Women’s Hospital","correspondingAuthor":true,"prefix":"","firstName":"Liqin","middleName":"","lastName":"Wang","suffix":""},{"id":334381866,"identity":"87086cf2-5a1c-4230-919b-33effdfe24f6","order_by":1,"name":"Richard Yang","email":"","orcid":"","institution":"Brigham and Women’s Hospital","correspondingAuthor":false,"prefix":"","firstName":"Richard","middleName":"","lastName":"Yang","suffix":""},{"id":334381867,"identity":"ce2b82d3-49e1-467a-8480-16836a950a71","order_by":2,"name":"Ziqin Sha","email":"","orcid":"","institution":"Lexington High School","correspondingAuthor":false,"prefix":"","firstName":"Ziqin","middleName":"","lastName":"Sha","suffix":""},{"id":334381868,"identity":"e41c8db4-f9b3-49da-bbf4-aab219921f74","order_by":3,"name":"Anna Maria Kuraszkiewicz","email":"","orcid":"","institution":"University of Massachusetts Amherst","correspondingAuthor":false,"prefix":"","firstName":"Anna","middleName":"Maria","lastName":"Kuraszkiewicz","suffix":""},{"id":334381869,"identity":"42a59a4c-b55f-479c-b34a-591f2bc9962b","order_by":4,"name":"Conrad Leonik","email":"","orcid":"","institution":"Louisiana State University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Conrad","middleName":"","lastName":"Leonik","suffix":""},{"id":334381870,"identity":"4edb7b9f-0ee3-4a79-a4be-80c3ae503c23","order_by":5,"name":"Li Zhou","email":"","orcid":"","institution":"Brigham and Women’s Hospital","correspondingAuthor":false,"prefix":"","firstName":"Li","middleName":"","lastName":"Zhou","suffix":""},{"id":334381871,"identity":"76966e99-fd64-4626-8c71-f0e5ed2892eb","order_by":6,"name":"Gad A. Marshall","email":"","orcid":"","institution":"Brigham and Women’s Hospital","correspondingAuthor":false,"prefix":"","firstName":"Gad","middleName":"A.","lastName":"Marshall","suffix":""}],"badges":[],"createdAt":"2024-07-02 05:16:50","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4671544/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4671544/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":62156937,"identity":"5a1b2ea7-c58b-47a4-b929-dbdce5fbd2cf","added_by":"auto","created_at":"2024-08-09 21:13:48","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":830523,"visible":true,"origin":"","legend":"\u003cp\u003ePRISMA flow diagram\u003c/p\u003e","description":"","filename":"Figure1PRISMAv22.png","url":"https://assets-eu.researchsquare.com/files/rs-4671544/v1/82de8be52d544d3794b8a7dd.png"},{"id":62155643,"identity":"2eb3c72b-4830-4665-b145-c3976c88fe8f","added_by":"auto","created_at":"2024-08-09 21:05:48","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":402934,"visible":true,"origin":"","legend":"\u003cp\u003eDistribution of articles by publication years, by type of risk factors. Four articles that were classified into more than one category have been counted under the medical condition category. \u003csup\u003e26, 32, 45, 61\u003c/sup\u003e\u003c/p\u003e","description":"","filename":"Figure2ArticlesYears.png","url":"https://assets-eu.researchsquare.com/files/rs-4671544/v1/50c452740f976320a5e6fd9a.png"},{"id":76131977,"identity":"7f110a06-fc25-49e4-b81e-cb5923ee56f9","added_by":"auto","created_at":"2025-02-12 15:32:08","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":2266853,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4671544/v1/3f58814a-825e-483e-9518-0877b4e1b9e8.pdf"},{"id":62155644,"identity":"1ff64898-add8-41e1-883c-2465666e067a","added_by":"auto","created_at":"2024-08-09 21:05:48","extension":"docx","order_by":4,"title":"","display":"","copyAsset":false,"role":"supplement","size":97557,"visible":true,"origin":"","legend":"","description":"","filename":"Supplementarytables.docx","url":"https://assets-eu.researchsquare.com/files/rs-4671544/v1/e00a289b8326491a156dde7d.docx"}],"financialInterests":"No competing interests reported.","formattedTitle":"Assessing Risk Factors for Cognitive Decline Using Electronic Health Record Data: A Scoping Review","fulltext":[{"header":"BACKGROUND","content":"\u003cp\u003eAlzheimer's disease (AD) presents a substantial global public health challenge, given its hallmark features of chronic cognitive and functional decline in older adults. The condition is commonly categorized into three stages based on cognitive impairment severity: preclinical, where individuals exhibit normal cognitive function with or without subtle concerns but have biological evidence of underlying AD; prodromal, marked by mild cognitive impairment (MCI); and the dementia stage, characterized by significant functional impairment affecting daily life.\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/sup\u003e As of 2023, a staggering 6.7\u0026nbsp;million Americans are living with AD in its dementia stage, with projections estimating this number to soar to 88\u0026nbsp;million by 2050.\u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e This not only poses a substantial financial burden but also profoundly impacts affected individuals, their families, and the healthcare system. Consequently, there is an urgent need to comprehensively grasp the risk factors associated with dementia and identify potential prevention and treatment strategies to mitigate this growing concern.\u003c/p\u003e \u003cp\u003eExisting studies have frequently relied on prospective datasets, which tend to suffer from limitations such as small sample sizes and underrepresentation of understudied populations, resulting in notable gaps in ADRD research.\u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u003c/sup\u003e There is a growing consensus in the scientific community on the necessity of exploring more extensive and diverse populations.\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eElectronic Health Record (EHR) data have proven pivotal in understanding the progression and outcomes of neurodegenerative diseases, particularly due to their chronic and gradually advancing nature. The widespread adoption of EHRs over recent decades has yielded a vast amount of longitudinal patient data. By sifting through these real-world datasets, we can gain deeper insights into the onset and evolution of AD and related dementias (ADRD), especially among populations that have been consistently engaged with the healthcare system. EHRs can be valuable in identifying potential risk factors for ADRD that might be missed in smaller convenience sample datasets. Moreover, they can highlight interventions that target certain medical problems that potentially affect the risk of dementia, particularly during early stages such as preclinical AD and MCI.\u003c/p\u003e \u003cp\u003eHowever, the extent to which EHR data have been utilized for such research remains unclear. While prior literature reviews have primarily focused on specific ADRD risk areas,\u003csup\u003e\u003cspan additionalcitationids=\"CR7\" citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e none, to our knowledge, has specifically addressed the utilization of EHR data for analyzing ADRD risks. Our study aims to fill this gap by concentrating on the identification of risk factors for cognitive decline, with a specific emphasis on MCI and dementia. We have intentionally excluded the preclinical stage of cognitive decline from our analysis due to diagnostic challenges in the clinical setting where biomarkers of AD are not commonly obtained prior to the stage of MCI. Through this scoping review, we aim to thoroughly aggregate existing literature on EHR data usage for studying these stages of cognitive decline and highlight potential areas for future research.\u003c/p\u003e"},{"header":"METHODS","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eSearch Strategy\u003c/h2\u003e \u003cp\u003eThis scoping review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.\u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e We conducted a Boolean search in PubMed, Web of Science, and CINAHL, identifying English-language studies published between January 1, 2010, and April 30, 2023. Our search included keywords related to cognitive impairment stages, such as dementia, MCI, and normal cognition, as well as EHR-related terms like \u0026ldquo;electronic health records\u0026rdquo;. The specific queries for individual databases can be found in \u003cb\u003eSupplementary Table\u0026nbsp;1\u003c/b\u003e. This study does not involve direct experimentation on human or animal subjects. All procedures and analyses comply with the ethical standards of the institution.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eStudy Selection\u003c/h2\u003e \u003cp\u003eWe included studies that utilized EHR datasets to investigate the association between potential risk factors and dementia outcomes. The EHR datasets referred to data extracted from EHR systems, not the active EHR systems themselves. We excluded review articles without original data, non-English articles, studies focused on patients with preexisting cognitive impairment at baseline, those with small sample size (n\u0026thinsp;\u0026lt;\u0026thinsp;100) or short follow-up times (\u0026lt;\u0026thinsp;1 year), non-epidemiology studies (e.g., algorithm evaluation), and studies of low-quality with missing or unclear components (e.g., unclear diagnostic criteria for outcomes).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eScreening Process\u003c/h2\u003e \u003cp\u003eAfter eliminating duplicates and using automation tools (e.g., classification by the search engine, keyword-based search of the tile and abstract) to exclude articles deemed ineligible, we obtained abstracts from the search results. Two reviewers independently assessed titles and abstracts based on the inclusion and exclusion criteria, resolving disagreements through discussion to reach a consensus. Subsequently, two reviewers independently performed full-text screening, with a senior reviewer addressing any disagreements.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eData Extraction\u003c/h2\u003e \u003cp\u003eWe extracted articles assessing risk factors for the cognitive decline onset, including MCI, AD, and other dementias. We assessed methodological quality and developed a data extraction schema based on the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist for observational studies.\u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e Extracted data included article information (authors and year), objectives, study design (e.g., cohort or case-control), study cohort, sample size, follow-up duration, data sources, explored risk factors, confounding variables, outcomes and measurement, statistical methods, and key findings. Each article underwent independent extraction by two reviewers, with discrepancies resolved through discussions, or consultation with a third reviewer.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003eArticle Classification\u003c/h2\u003e \u003cp\u003eAfter extracting risk factors from articles, we categorized them into major groups, including medical conditions, medical interventions, lifestyle, socioeconomic, psychosocial, and environmental factors. These groups were further subdivided; for example, medical conditions included cardiovascular and metabolic conditions, as well as psychiatric conditions. Some articles covered multiple risk factors, leading to overlap across categories.\u003c/p\u003e \u003c/div\u003e"},{"header":"RESULTS","content":"\u003cp\u003eFigure \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e shows the PRISMA flow diagram. The initial search yielded 1,593 articles, 565 from PubMed, 538 from Web of Science, and 490 from CINAHL. We removed 496 duplicate articles, where the same article appeared in more than one database. Automated tools marked 74 articles as ineligible, which included 3 case reports, 28 review articles, and 43 articles without abstracts. We also excluded 95 additional records, such as 42 datasets, 25 preprints, 13 authorless articles, 9 patents, 3 genetic studies, 2 books, and 1 thesis. Subsequently, during title and abstract screening, 832 articles were excluded for not meeting the criteria. The remaining 96 articles underwent full-text screening. After excluding additional 16 articles, e.g., those not primarily using EHR data, or having small sample size, 80 articles remained for final analysis. A detailed list of these articles and extracted data is available in \u003cb\u003eSupplementary Table\u0026nbsp;2\u003c/b\u003e in the supplement.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003eResearch Trend Over Time\u003c/h2\u003e \u003cp\u003eFigure \u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e illustrates the distribution of analyzed articles by publication year. It shows a notable increase in publications related to our topic over the past decade, indicating a growing trend in using EHR data to examine ADRD risk factors. Although our search spanned from 2010 to 2023, all included articles were published after 2014. More than one-quarter of the articles (n\u0026thinsp;=\u0026thinsp;22, 27.5%) were published in 2022. It is important to note that our search was conducted up to April 2023; therefore, the total for that year does not reflect the full annual count.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003eStudy Design\u003c/h2\u003e \u003cp\u003eOut of the 80 articles reviewed, 77(96.3%) were longitudinal studies retrospectively conducted, comprising 70 cohort studies, six case-control studies, and one randomized control trial. Longitudinal studies had a median EHR duration of 16 years, calculated from the initial year to the final year of the EHR records utilized, regardless of individual patient follow-up time. Among these, 16 studies (20%) had EHR data spanning under 10 years, 39 studies (48.8%) ranged between 10 and 20 years, and 22 studies (27.5%) had data duration exceeding 20 years.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eMethods for Statistical Analyses\u003c/h2\u003e \u003cp\u003eIn the statistical analysis, 76.3% of the studies (n\u0026thinsp;=\u0026thinsp;61) predominantly used survival analysis to model and identify various risk or protective factors. Among these, most (n\u0026thinsp;=\u0026thinsp;54, 88.5%) opted for the Cox proportional-hazards regression model,\u003csup\u003e\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003e while some (n\u0026thinsp;=\u0026thinsp;13, 21%) used the Fine-Gray model,\u003csup\u003e\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u003c/sup\u003e often in combination. The Fine-Gray model was chosen for its ability to handle competing risks like death. Other statistical analysis methods included logistic regression, Chi-squared test, and analysis of variance (ANOVA).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003eEHR Datasets and Sources\u003c/h2\u003e \u003cp\u003eThe included articles utilized diverse datasets to examine ADRD risk factors. These datasets were derived either directly from EHR systems, such as Veterans Health Administration (VHA), or linked to EHR databases to incorporate specific variables or outcomes from external databases, such as the UK Biobank. Categorized by geographical location, almost half of the studies (46.3%, n\u0026thinsp;=\u0026thinsp;37) used data from EHR systems within the United States (US), while 40% (n\u0026thinsp;=\u0026thinsp;32) utilized datasets from the United Kingdom (UK). Additional countries represented in this review included Australia (n\u0026thinsp;=\u0026thinsp;3),\u003csup\u003e13\u0026ndash;15\u003c/sup\u003e China (n\u0026thinsp;=\u0026thinsp;3),\u003csup\u003e16\u0026ndash;18\u003c/sup\u003e Denmark (n\u0026thinsp;=\u0026thinsp;3),\u003csup\u003e19\u0026ndash;21\u003c/sup\u003e the Netherlands (n\u0026thinsp;=\u0026thinsp;3),\u003csup\u003e20\u0026ndash;22\u003c/sup\u003e Taiwan (n\u0026thinsp;=\u0026thinsp;2),\u003csup\u003e23, \u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e Canada (n\u0026thinsp;=\u0026thinsp;2),\u003csup\u003e25, \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e and Sweden (n\u0026thinsp;=\u0026thinsp;2).\u003csup\u003e27, \u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eIn the US, the most frequently used EHR dataset was derived from the Kaiser Permanente\u0026rsquo;s EHR (11 studies), followed by the VHA (6 studies). The remaining 21 articles used databases from other US healthcare systems and commercial sources like TriNetX,\u003csup\u003e\u003cspan additionalcitationids=\"CR30\" citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e IBM Explorys,\u003csup\u003e\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u003c/sup\u003e and Optum.\u003csup\u003e\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u003c/sup\u003e For studies utilizing UK datasets, the Whitehall II study\u003csup\u003e\u003cspan additionalcitationids=\"CR35 CR36 CR37 CR38\" citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e\u003c/sup\u003e (n\u0026thinsp;=\u0026thinsp;8) and UK biobank\u003csup\u003e\u003cspan additionalcitationids=\"CR41 CR42 CR43 CR44 CR45\" citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e\u003c/sup\u003e (n\u0026thinsp;=\u0026thinsp;7) cohorts were the most frequently used, linked to various UK EHR datasets, including the Hospital Episode Statistics,\u003csup\u003e\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e\u003c/sup\u003e Scottish Morbidity Record data,\u003csup\u003e\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e\u003c/sup\u003e and Patient Episode Database.\u003csup\u003e\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e, \u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e, \u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e\u003c/sup\u003e Other frequently used databases in the UK studies included the Clinical Practice Research Datalink (n\u0026thinsp;=\u0026thinsp;6)\u003csup\u003e49\u0026ndash;53\u003c/sup\u003e and the Health Improvement Network (THIN) (n\u0026thinsp;=\u0026thinsp;4).\u003csup\u003e21, \u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e, \u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003eEHR Dataset Sample Size\u003c/h2\u003e \u003cp\u003eThe studies employed datasets with varying sample sizes, from hundred to millions of patients. Only one study had fewer than 1000 patients.\u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e Twenty-six (32.5%) studies had datasets ranging from 1,000 to 10,000 patients; 46 (57.5%) studies had datasets with 10,000 to one million patients. Seven (8.8%) studies used datasets with over one million patients.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003eOutcomes and Measurements\u003c/h2\u003e \u003cp\u003eMost studies (n\u0026thinsp;=\u0026thinsp;67) examined multiple dementia subtypes, including AD, vascular dementia, Lewy body dementia (LBD), frontotemporal dementia (FTD), and mixed dementia. AD was consistently included in all studies, with nine studies exclusively focused on AD. The majority of these studies defined outcomes using standard coding systems, such as ICD codes (81.3%, n\u0026thinsp;=\u0026thinsp;65), Read codes (11.3%, n\u0026thinsp;=\u0026thinsp;9), and SNOMED-CT (2.5%, n\u0026thinsp;=\u0026thinsp;2). Additionally, some studies employed alternative methods, including prescriptions for dementia medications,\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e, \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e, \u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u003c/sup\u003e cognitive function tests,\u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e, \u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e, \u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e\u003c/sup\u003e referencing the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition),\u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e, \u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e, \u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e58\u003c/span\u003e\u003c/sup\u003e screening interviews,\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e\u003c/sup\u003e and neuroimaging.\u003csup\u003e\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003eRisk and Protective Factors\u003c/h2\u003e \u003cp\u003eWe summarized the analyzed risk factors in the reviewed articles, categorizing medical conditions and interventions into broad disease categories (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). Other risk factors were classified into lifestyle, socioeconomic, environmental, and miscellaneous categories (Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eSummary of medical conditions and interventions from EHR-based studies in related to the risk of Alzheimer\u0026rsquo;s disease and related dementias.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003eMedical conditions (n\u0026thinsp;=\u0026thinsp;39)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003eMedical interventions (n\u0026thinsp;=\u0026thinsp;25)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCategories\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo. of articles\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eRisk Factors/Exposures\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNo. of articles\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eRisk Factors/Exposures\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCardiovascular and metabolic\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eDiabetes\u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e, \u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e, \u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e, \u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eHypoglycemia in diabetic patients\u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e, \u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e, \u003cspan citationid=\"CR62\" class=\"CitationRef\"\u003e62\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eHypertension\u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e, \u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e63\u003c/span\u003e, \u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e\u003c/sup\u003e\u0026harr;\u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eHypotension \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eHigh blood pressure variability \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e65\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eCoronary artery disease \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eStroke \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eHyperlipidemia \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eDyslipidemia \u0026harr;\u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eObesity \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e\u003c/sup\u003e \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e \u0026harr;\u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eAntihypertensive medications \u0026harr;\u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eAspirin \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eStatins \u0026harr;\u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eRosuvastatin \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR76\" class=\"CitationRef\"\u003e76\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eAnticoagulant \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e\u003c/sup\u003ea\u003c/p\u003e \u003cp\u003eTelmisartan \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eMetformin \u0026harr;\u003csup\u003e\u003cspan citationid=\"CR77\" class=\"CitationRef\"\u003e77\u003c/span\u003e\u003c/sup\u003e \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u003c/sup\u003eb\u003c/p\u003e \u003cp\u003eThiazolidinedione \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR78\" class=\"CitationRef\"\u003e78\u003c/span\u003e\u003c/sup\u003ec\u003c/p\u003e \u003cp\u003eSulfonylurea \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e, \u003cspan citationid=\"CR78\" class=\"CitationRef\"\u003e78\u003c/span\u003e\u003c/sup\u003ec\u003c/p\u003e \u003cp\u003eMetformin and thiazolidinedione dual therapy \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR78\" class=\"CitationRef\"\u003e78\u003c/span\u003e\u003c/sup\u003ec\u003c/p\u003e \u003cp\u003eSodium-glucose co-transporter 2 inhibitors \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eCarotid endarterectomy \u0026harr;\u003csup\u003e\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eBariatric surgery \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR79\" class=\"CitationRef\"\u003e79\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eInfections, inflammatory, and immune-related\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eHIV \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR66\" class=\"CitationRef\"\u003e66\u003c/span\u003e, \u003cspan citationid=\"CR67\" class=\"CitationRef\"\u003e67\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eE. coli \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR68\" class=\"CitationRef\"\u003e68\u003c/span\u003e\u003c/sup\u003ee\u003c/p\u003e \u003cp\u003eHerpes zoster \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eCovid-19 \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eSymptomatic herpes simplex virus infection \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR69\" class=\"CitationRef\"\u003e69\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eCommon infections (sepsis, pneumonia, other LRTIs, UTIs and SSTIs) \u0026harr;\u003csup\u003e\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eInflammatory/autoimmune conditions \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eInflammatory Bowel Disease \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eHigh urate \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eGout \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eTumor necrosis factor blocking agent \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e, \u003cspan citationid=\"CR80\" class=\"CitationRef\"\u003e80\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eMethotrexate \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e, \u003cspan citationid=\"CR80\" class=\"CitationRef\"\u003e80\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eNSAIDs \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eAntiherpetic medication \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eImmunomodulators \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNeurological/ophthalmological conditions\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eRetinal vascular occlusion \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e58\u003c/span\u003e\u003c/sup\u003e \u0026harr;\u003csup\u003e\u003cspan citationid=\"CR71\" class=\"CitationRef\"\u003e71\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eVisual impairment \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eDiabetic retinopathy \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR72\" class=\"CitationRef\"\u003e72\u003c/span\u003e\u003c/sup\u003e \u0026harr;\u003csup\u003e\u003cspan citationid=\"CR73\" class=\"CitationRef\"\u003e73\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eTraumatic brain injury \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR74\" class=\"CitationRef\"\u003e74\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eEpilepsy \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR75\" class=\"CitationRef\"\u003e75\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eCataract extraction \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePhysical function and frailty\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eLow physical function \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003ePhysical inactivity \u0026harr;\u003csup\u003e\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eUnderweight \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e, \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e, \u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e \u0026harr;\u003csup\u003e\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eLow caloric intake \u0026harr;\u003csup\u003e\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003en/a\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePsychiatric\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eDepression \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e, \u003cspan citationid=\"CR70\" class=\"CitationRef\"\u003e70\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003ePsychotic disorder \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eSSRI \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR81\" class=\"CitationRef\"\u003e81\u003c/span\u003e\u003c/sup\u003e \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR76\" class=\"CitationRef\"\u003e76\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eTrazodone \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e\u003c/sup\u003ee\u003c/p\u003e \u003cp\u003eBenzodiazepines \u0026harr;\u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOncology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eCancer \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eSkin cancer \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eAndrogen deprivation therapy \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR82\" class=\"CitationRef\"\u003e82\u003c/span\u003e, \u003cspan citationid=\"CR83\" class=\"CitationRef\"\u003e83\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eAromatase inhibitor therapy versus tamoxifen \u0026harr;\u003csup\u003e\u003cspan citationid=\"CR84\" class=\"CitationRef\"\u003e84\u003c/span\u003e\u003c/sup\u003ed\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOther\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eKidney disease \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eHip fracture \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eOsteoarthritis \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eβ-antagonists \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eVitamin D \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eOmeprazole \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR76\" class=\"CitationRef\"\u003e76\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eSummary of lifestyles, socioeconomic, psychosocial, environmental and other factors from EHR-based studies in related to the risk of Alzheimer\u0026rsquo;s disease and related dementias.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCategories\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNo. of articles\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eRisk Factors/Exposures\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"3\" nameend=\"c3\" namest=\"c1\"\u003e \u003cp\u003eLifestyle, socioeconomic, psychosocial, environmental risk factors (n\u0026thinsp;=\u0026thinsp;14)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eLifestyle\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eDiet \u0026harr;\u003csup\u003e\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e, \u003cspan citationid=\"CR85\" class=\"CitationRef\"\u003e85\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eHealthy lifestyle \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eSmoking \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eAlcohol consumption \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eSocioeconomic\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eHigh education \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR86\" class=\"CitationRef\"\u003e86\u003c/span\u003e, \u003cspan citationid=\"CR87\" class=\"CitationRef\"\u003e87\u003c/span\u003e\u003c/sup\u003e \u0026harr;\u003csup\u003e\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eNeighborhood disadvantage \u0026uarr; \u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e, \u003cspan citationid=\"CR88\" class=\"CitationRef\"\u003e88\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eLow occupational position \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePsychosocial\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSocial isolation \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eSocial contact \u0026darr;\u003csup\u003e\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eFeeling of loneliness \u0026harr;\u003csup\u003e\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEnvironmental\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eBirth in high stroke mortality states \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR89\" class=\"CitationRef\"\u003e89\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eAgent orange \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR90\" class=\"CitationRef\"\u003e90\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eLithium level in drinking water \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR91\" class=\"CitationRef\"\u003e91\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003eOthers (n\u0026thinsp;=\u0026thinsp;8)\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eOthers\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePlasma protein \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eLower testosterone \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eHigher brain age \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR103\" class=\"CitationRef\"\u003e103\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eLow Childhood IQ \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR104\" class=\"CitationRef\"\u003e104\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eICU admission \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR105\" class=\"CitationRef\"\u003e105\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eHispanic race \u0026uarr;\u003csup\u003e\u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eSex \u0026harr;\u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eCRP genotype \u0026harr;\u003csup\u003e\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003eApolipoprotein E (APOE) genotype \u0026harr;\u003csup\u003e\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec16\" class=\"Section2\"\u003e \u003ch2\u003eMedical conditions\u003c/h2\u003e \u003cp\u003eOut of the 80 articles reviewed, 39 (48.8%) explored the interplay between medical conditions and ADRD. Of them, 15 articles focused on cardiovascular and metabolic conditions, 11 on infections, inflammatory and immune-related conditions, 7 on neurological/ophthalmological conditions, 5 on physical function and frailty, 4 on psychiatric conditions, 2 on cancer,\u003csup\u003e\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e, \u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e\u003c/sup\u003e and 4 on other risk factors like kidney disease,\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e\u003c/sup\u003e osteoarthritis,\u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e and hip fracture.\u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003cp\u003e \u003cem\u003eCardiovascular and metabolic conditions\u003c/em\u003e: A significant finding in our analysis is the association of cardiovascular/metabolic conditions and ADRD risk. Diabetes, examined in several studies,\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e, \u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e, \u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e, \u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e\u003c/sup\u003e and its common complication, hypoglycemia, identified as a risk factor,\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e, \u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e, \u003cspan citationid=\"CR62\" class=\"CitationRef\"\u003e62\u003c/span\u003e\u003c/sup\u003e are noteworthy. Extensive research using EHR data has explored blood pressure\u0026rsquo;s relationship with ADRD. Hypertension,\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e, \u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e63\u003c/span\u003e, \u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e\u003c/sup\u003e hypotension\u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e and blood pressure variability,\u003csup\u003e\u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e65\u003c/span\u003e\u003c/sup\u003e all contribute to increased ADRD risk. Additional risk factors include coronary artery disease,\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e stroke,\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e and hyperlipidemia.\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e Obesity\u0026rsquo;s impact is mixed: it has been identified as a risk factor in one study,\u003csup\u003e\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e\u003c/sup\u003e suggested to have a potential protective effect in another,\u003csup\u003e\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e and found to have no impact in a third,\u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e, \u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e\u003c/sup\u003e although this may be influenced by factors like age at assessment and frailty in underweight individuals.\u003c/p\u003e \u003cp\u003e \u003cstrong\u003eInfections, inflammatory and immune-related conditions\u003c/strong\u003e \u003cp\u003eHIV,\u003csup\u003e\u003cspan citationid=\"CR66\" class=\"CitationRef\"\u003e66\u003c/span\u003e, \u003cspan citationid=\"CR67\" class=\"CitationRef\"\u003e67\u003c/span\u003e\u003c/sup\u003e E. coli,\u003csup\u003e\u003cspan citationid=\"CR68\" class=\"CitationRef\"\u003e68\u003c/span\u003e\u003c/sup\u003e and Covid-19\u003csup\u003e29\u003c/sup\u003e have been identified as risk factors for ADRD. However, several common infections\u0026ndash;such as sepsis, pneumonia, lower respiratory tract infections, urinary tract infections, and skin and soft tissue infections\u0026ndash;did not exhibit increased ADRD risk.\u003csup\u003e\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e\u003c/sup\u003e Regarding herpes viruses, one study observed a slightly decreased risk of dementia among individuals with symptomatic Herpes Simplex Virus 1 (HSV-1) infections untreated by antivirals and a more pronounced 25% decrease in those treated with antivirals.\u003csup\u003e\u003cspan citationid=\"CR69\" class=\"CitationRef\"\u003e69\u003c/span\u003e\u003c/sup\u003e Another study detected a minor protective link between Herpes Zoster (HZ) and dementia, particularly in frail individuals and females, and only for mixed or unspecified dementia.\u003csup\u003e\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e\u003c/sup\u003e Additionally, the inflammatory/autoimmune disease cluster was associated with elevated ADRD risk,\u003csup\u003e\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e\u003c/sup\u003e including inflammatory bowel disease was also found as a risk factor.\u003csup\u003e\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u003c/sup\u003e Both high urate\u003csup\u003e\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e and gout\u003csup\u003e\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e\u003c/sup\u003e were associated with a decreased risk for ADRD, possibly due to uric acid\u0026rsquo;s antioxidant effects, which align with observations related to obesity.\u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003ePsychiatric conditions\u003c/strong\u003e \u003cp\u003eThe interplay between depression and ADRD remains unclear. While some view depression as a symptom, others see it as a precursor. In our final analysis, three articles explored the link, and all identified a depression as a risk factor for ADRD.\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e, \u003cspan citationid=\"CR70\" class=\"CitationRef\"\u003e70\u003c/span\u003e\u003c/sup\u003e Additionally, psychotic disorders have been reported as a risk factor.\u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eNeurological/ophthalmological conditions\u003c/strong\u003e \u003cp\u003eThe eyes and brain also form crucial nodes in the ADRD risk network. Retinal vascular occlusion is linked to increased ADRD risk.\u003csup\u003e\u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e58\u003c/span\u003e\u003c/sup\u003e Visual impairment, assessed by visual acuity, has also been linked to an elevated ADRD risk,\u003csup\u003e\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e\u003c/sup\u003e although one study did not find this connection.\u003csup\u003e\u003cspan citationid=\"CR71\" class=\"CitationRef\"\u003e71\u003c/span\u003e\u003c/sup\u003e The impact of diabetic retinopathy, a complication from diabetes, remains ambiguous, with one study indicating increased risk\u003csup\u003e\u003cspan citationid=\"CR72\" class=\"CitationRef\"\u003e72\u003c/span\u003e\u003c/sup\u003e and another observed no effect.\u003csup\u003e\u003cspan citationid=\"CR73\" class=\"CitationRef\"\u003e73\u003c/span\u003e\u003c/sup\u003e Traumatic brain injury\u003csup\u003e\u003cspan citationid=\"CR74\" class=\"CitationRef\"\u003e74\u003c/span\u003e\u003c/sup\u003e and epilepsy\u003csup\u003e\u003cspan citationid=\"CR75\" class=\"CitationRef\"\u003e75\u003c/span\u003e\u003c/sup\u003e are identified as risk factors.\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003ePhysical function and frailty\u003c/strong\u003e \u003cp\u003eFrailty metrics are factors to consider in ADRD risk assessment. Underweight is identified as a risk factor for ADRD,\u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e, \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e, \u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e although one study had a different finding.\u003csup\u003e\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e\u003c/sup\u003e The protective effect of obesity, sometimes observed, could be related to avoiding the increased risk associated with being underweight.\u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e Low physical function, measured by grip strength and the Short Physical Performance Battery (SPPB), is linked to increased risk.\u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e However, another study did not find an association between physical inactivity or unintentional low caloric intake and ADRD risk.\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eOther medical conditions\u003c/strong\u003e \u003cp\u003eSeveral studies have investigated a miscellany of medical conditions in related to ADRD. Cancer is noteworthy, with one study showing an elevated ADRD risk in the cancer disease cluster.\u003csup\u003e\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e\u003c/sup\u003e In contrast, another study found that malignant melanoma and non-melanoma skin cancers were associated with a reduced ADRD risk, suggesting a protective effect.\u003csup\u003e\u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e\u003c/sup\u003e Additionally, kidney disease,\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e\u003c/sup\u003e hip fracture,\u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e and osteoarthritis\u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e were identified as ADRD risk factors.\u003c/p\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec17\" class=\"Section2\"\u003e \u003ch2\u003eMedical interventions\u003c/h2\u003e \u003cp\u003eIn light of the risk posed by medical conditions to ADRD, researchers have examined various medical interventions to determine if they could mitigate the risk of ADRD. Of the 80 articles assessed, 25 (31.3%) analyzed the association between medical interventions and ADRD. Out of these, 11 were related to cardiovascular and metabolic interventions, 5 to immune, infection, and inflammatory interventions, 4 to psychiatric interventions, 3 to oncology, and 4 to other interventions.\u003c/p\u003e \u003cp\u003e \u003cstrong\u003eCardiovascular and metabolic-related interventions\u003c/strong\u003e \u003cp\u003eResearch has focused on treatments targeting cardiovascular and metabolic conditions to reduce ADRD risk. Medications such as rosuvastatin,\u003csup\u003e\u003cspan citationid=\"CR76\" class=\"CitationRef\"\u003e76\u003c/span\u003e\u003c/sup\u003e telmisartan,\u003csup\u003e\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e anticoagulants,\u003csup\u003e\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e\u003c/sup\u003e and aspirin,\u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e primarily for cardiovascular health, have proven effective in lowering ADRD risk. In diabetes management, metformin showed no association with incident dementia compared to no initial treatment within the first 6 months post-diagnosis.\u003csup\u003e\u003cspan citationid=\"CR77\" class=\"CitationRef\"\u003e77\u003c/span\u003e\u003c/sup\u003e However, it presented a mild protective effect compared to sulfonylureas.\u003csup\u003e\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e, \u003cspan citationid=\"CR78\" class=\"CitationRef\"\u003e78\u003c/span\u003e\u003c/sup\u003e Conversely, thiazolidinedione monotherapy and combined therapy with metformin reduced ADRD risk compared to metformin alone.\u003csup\u003e\u003cspan citationid=\"CR78\" class=\"CitationRef\"\u003e78\u003c/span\u003e\u003c/sup\u003e Sodium-glucose co-transporter 2 inhibitors decreased the risk of dementia in patients with atrial fibrillation and type 2 diabetes.\u003csup\u003e\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e Among surgical interventions, bariatric surgery increased ADRD risk,\u003csup\u003e\u003cspan citationid=\"CR79\" class=\"CitationRef\"\u003e79\u003c/span\u003e\u003c/sup\u003e while carotid endarterectomy had no discernible impact.\u003csup\u003e\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eImmune, infection and inflammatory-related interventions\u003c/strong\u003e \u003cp\u003eImmune, infection and inflammatory-related interventions, such as tumor necrosis factor blocking agent,\u003csup\u003e\u003cspan citationid=\"CR80\" class=\"CitationRef\"\u003e80\u003c/span\u003e\u003c/sup\u003e methotrexate\u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e and antiherpetic medications,\u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e were found to have protective effects against ADRD, while nonsteroidal anti-inflammatory drugs (NSAIDs)\u003csup\u003e\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e\u003c/sup\u003e were observed to increase the risk.\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003ePsychiatric-related interventions\u003c/strong\u003e \u003cp\u003eStudies had contradictory conclusions on the impact of the selective serotonin reuptake inhibitor (SSRI) antidepressant class on ADRD risk, with one suggesting it as a risk factor\u003csup\u003e\u003cspan citationid=\"CR81\" class=\"CitationRef\"\u003e81\u003c/span\u003e\u003c/sup\u003e and the other as protective.\u003csup\u003e\u003cspan citationid=\"CR76\" class=\"CitationRef\"\u003e76\u003c/span\u003e\u003c/sup\u003e Trazodone, another serotonergic antidepressant often used for insomnia, was reported as a neutral factor.\u003csup\u003e\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eOncology and other Interventions\u003c/strong\u003e \u003cp\u003eAndrogen deprivation therapy was linked to an increased risk for ADRD in two studies by the same team.\u003csup\u003e\u003cspan citationid=\"CR82\" class=\"CitationRef\"\u003e82\u003c/span\u003e, \u003cspan citationid=\"CR83\" class=\"CitationRef\"\u003e83\u003c/span\u003e\u003c/sup\u003e However, aromatase inhibitor therapy and tamoxifen, used for hormone receptor-positive breast cancer, did not show a difference in dementia risk.\u003csup\u003e\u003cspan citationid=\"CR84\" class=\"CitationRef\"\u003e84\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec18\" class=\"Section2\"\u003e \u003ch2\u003eLifestyle, socioeconomic, psychosocial and environmental factors\u003c/h2\u003e \u003cp\u003eEHR data have been utilized to examine the influence of lifestyle, socioeconomic, psychosocial, and environmental factors on ADRD. Out of the reviewed articles, 14 (17.5%) were related to this topic, with 5 articles focused on lifestyles, 5 on socioeconomic factors, 3 on environmental factors, and 2 on psychosocial factors.\u003c/p\u003e \u003cp\u003e \u003cstrong\u003eLifestyle\u003c/strong\u003e \u003cp\u003eBoth smoking\u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e and extensive alcohol consumption\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e were identified as risk factors for ADRD. Conversely, a healthy lifestyle, including no current smoking, moderate alcohol consumption, regular physical activity, healthy diet, adequate sleep duration, less sedentary behavior, and frequent social contact, exhibited a protective effect against ADRD in patients with type II diabetes.\u003csup\u003e\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e\u003c/sup\u003e However, diet alone was not found to be protective against ADRD.\u003csup\u003e\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e, \u003cspan citationid=\"CR85\" class=\"CitationRef\"\u003e85\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eSocioeconomic factors\u003c/strong\u003e \u003cp\u003eHigher education showed neuroprotective effects in two of three studies on education and ADRD risk,\u003csup\u003e\u003cspan citationid=\"CR86\" class=\"CitationRef\"\u003e86\u003c/span\u003e, \u003cspan citationid=\"CR87\" class=\"CitationRef\"\u003e87\u003c/span\u003e\u003c/sup\u003e although the third study found no significant correlation.\u003csup\u003e\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e\u003c/sup\u003e Neighborhood disadvantage\u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e, \u003cspan citationid=\"CR88\" class=\"CitationRef\"\u003e88\u003c/span\u003e\u003c/sup\u003e and low occupational position\u003csup\u003e\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e\u003c/sup\u003e were associated to a higher risk of ADRD.\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003ePsychosocial factors\u003c/strong\u003e \u003cp\u003ePsychosocial factors such as social isolation have been identified as risk factors for ADRD.\u003csup\u003e\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e\u003c/sup\u003e In contrast, frequent social contact appears to be a protective factor.\u003csup\u003e\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e\u003c/sup\u003e Another metric, the \u0026ldquo;feeling of loneliness,\u0026rdquo; was not associated with an increased or decreased risk.\u003csup\u003e\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/p\u003e \u003cp\u003e \u003cstrong\u003eEnvironmental factors\u003c/strong\u003e \u003cp\u003eEHR data was used to analyze several environmental risk factors for ADRD. Being born in high stroke mortality states\u003csup\u003e\u003cspan citationid=\"CR89\" class=\"CitationRef\"\u003e89\u003c/span\u003e\u003c/sup\u003e and exposure to Agent Orange among veterans\u003csup\u003e\u003cspan citationid=\"CR90\" class=\"CitationRef\"\u003e90\u003c/span\u003e\u003c/sup\u003e were found to be associated with an increased risk of ADRD. Additionally, lithium levels in drinking water were associated with greater risk of dementia in women.\u003csup\u003e\u003cspan citationid=\"CR91\" class=\"CitationRef\"\u003e91\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"DISCUSSION","content":"\u003cp\u003eIn this scoping review, we conducted comprehensive searches across three major databases to identify studies that utilized EHR data to analyze risk factors associated with cognitive decline. The final selection of 80 articles spans a wide range of risk factors, including medical conditions, interventions, lifestyle, socioeconomic status, psychosocial, and environmental factors. The majority of studied medical conditions were associated with an elevated risk of ADRD, whereas medical interventions addressing these conditions often reduced the ADRD risk. Using large and diverse EHR datasets has enriched the literature on antecedent risk factors for dementia and confirmed findings from smaller sample studies.\u003c/p\u003e \u003cp\u003eLongitudinal EHR data are essential for ADRD research due to the slow progression of the disease. The prolonged latency period between risk factor exposure and clinical symptoms necessitates extended observation to identify early signs and risk factors, facilitating causality assessment.\u003c/p\u003e \u003cp\u003eUtilizing EHR datasets offers numerous benefits for ADRD research. These datasets provide extensive data with a wealth of variables, enabling the exploration of diverse medical conditions and interventions to identify risk and protective factors for cognitive impairment and dementia. These datasets allow simultaneously investigation of multiple potential risk and protective factors while enabling comprehensive adjustments for confounders. Access to large and diverse EHR datasets enhances statistical power,\u003csup\u003e\u003cspan citationid=\"CR92\" class=\"CitationRef\"\u003e92\u003c/span\u003e\u003c/sup\u003e allowing for the study of rare events and the identification of unique risk profiles and disease trajectories.\u003csup\u003e\u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e, \u003cspan citationid=\"CR90\" class=\"CitationRef\"\u003e90\u003c/span\u003e\u003c/sup\u003e These datasets encompass individuals from various backgrounds, facilitating research across different populations and the examination of various disease subtypes and clinical presentation variations. EHR offers rich, detailed clinical data that enable in-depth studies into the clinical aspects and mechanisms of ADRD. Additionally, EHR datasets can confirm and provide unique insights into factors sometimes overlooked or absent in other types of studies.\u003c/p\u003e \u003cp\u003eTo facilitate the investigation of risk factors, including socioeconomic aspects, lifestyle, and environmental factors, EHR data are often linked to external datasets using patient identifiers like names, social security numbers, and zip codes. This approach enables the exploration of additional factors and the incorporation of confounding variables from the EHR.\u003c/p\u003e \u003cp\u003eThe utilization of EHR data has the potential to help identify new risk factors for ADRD, as well as analyze the traditionally recognized risk factors from a new perspective. Traditional risk factors, such as diabetes,\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e, \u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e, \u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e, \u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e\u003c/sup\u003e hypertension,\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e, \u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e63\u003c/span\u003e, \u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e\u003c/sup\u003e stroke,\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e hyperlipidemia,\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e and traumatic brain injury,\u003csup\u003e\u003cspan citationid=\"CR74\" class=\"CitationRef\"\u003e74\u003c/span\u003e\u003c/sup\u003e have been confirmed in the studies utilizing EHR data. Additionally, our review presents a list of newly recognized potential risk factors emerging from EHR data analysis. These include but are not limited to, environmental exposures like Agent Orange,\u003csup\u003e\u003cspan citationid=\"CR90\" class=\"CitationRef\"\u003e90\u003c/span\u003e\u003c/sup\u003e infections such as COVID-19,\u003csup\u003e\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e and certain surgical procedures previously not associated with ADRD risk. The study by Kim et al,\u003csup\u003e\u003cspan citationid=\"CR79\" class=\"CitationRef\"\u003e79\u003c/span\u003e\u003c/sup\u003e for example, was the first to find that bariatric surgery increases the risk of ADRD, which contrasts with earlier research that has suggested potential cognitive benefits related to weight loss and metabolic improvement post-surgery. The advent of big data has enabled the identification of these novel risk factors, offering fresh insights into the multifactorial nature of ADRD.\u003c/p\u003e \u003cp\u003eExploring various populations and EHR datasets reveals inconsistencies in findings on factors like obesity, hypertension, visual impairment, metformin, and underweight, as well as potential conflicts with results from studies not included in this review. The divergent findings underscore the complexity of ADRD risk factors, emphasizing the importance of further research to elucidate these relationships.\u003c/p\u003e \u003cp\u003eUsing EHR datasets for ADRD research offers valuable insights but comes with notable limitations. The accuracy and completeness of diagnostic coding in EHRs can vary, impacting the reliability of outcome and exposure classification. Another constraint is the outcome measure heterogeneity and quality in EHR-based studies. Dementia definitions vary, including or excluding subtypes like vascular dementia and LBD, and using different coding systems (ICD, SNOMED CT, READ). Some use cognitive tests with smaller samples, while others rely on ICD codes for larger samples but potentially less specific diagnoses. This diversity in dementia definitions reflects the complexity of diagnosing and classifying cognitive decline and dementia in real-world clinical settings. It affects the identification of cognitive decline risk factors, leading to variability in reported associations. For instance, studies focusing on specific dementia subtypes may reveal unique risk factors that differ from those identified in broader dementia studies. The choice of diagnostic codes and cognitive assessments can also influence the accuracy of dementia identification, thereby affecting the strength and direction of associations between risk factors and cognitive decline. Minimizing variability in outcome measures could substantially enhance the interpretability and comparability of findings in cognitive decline research. Standardizing the criteria for dementia diagnosis across majority of healthcare providers, as opposed to limiting it to a few specialists (dementia experts), could simplify the synthesis of research results and refine the accuracy of associations with risk factor. It could also enhance the detection of subtle or nuanced associations between risk factors and cognitive decline that might be obscured by the current heterogeneity.\u003c/p\u003e \u003cp\u003eEHR-based studies provide valuable insights but do not conclusively establish causality due to the potential influence of uncontrolled confounding variables. Investigations into the link between depression and dementia highlight this challenge. Studies related to diabetes management often fail to distinguish between the cognitive effects of specific diabetes medications and those resulting from overall glycemic control, leaving it unclear if observed benefits stem from particular drugs or general blood sugar management. Additionally, trazodone was found as a risk factor for ADRD; however, the study suggests that the higher incidence of dementia observed among trazodone users might not imply a direct causal relationship but could instead reflect the medication's use in managing symptoms common in the early stages of cognitive impairment.\u003csup\u003e\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e\u003c/sup\u003e Therefore, when interpreting results from those included observational studies, readers should be cautious not to presume a direct causal relationship between the risk factors studied and the outcomes.\u003c/p\u003e \u003cp\u003eFurthermore, the inherent biases in observational studies, including potential confounding, selection bias, and information bias, continue to be pervasive issues. Although most included studies attempted to adjust for known confounders, the possibility of residual confounding cannot be dismissed. Adjusting for confounders in survival models may not be sufficient, especially with numerous confounders or significant covariate overlap between the groups being compared. This can lead to issues such as multicollinearity and overfitting. Advanced statistical methods, including propensity score matching (PSM) and inverse probability weighting (IPW), are often used to reduce bias in the estimation of exposure or treatment effects. Nevertheless, EHR-based studies are not equivalent to randomized controlled clinical trials, the gold standard for establishing causality. Researchers should also consider the context of EHR data collection, including demographic and clinical characteristics of study populations. Variations in healthcare access and utilization across different populations could influence the observed associations. Notably, crucial data, such as information on deaths, may be absent from the EHRs. While some studies have cross-referenced EHR data with external databases to create more comprehensive datasets, not all have followed this approach.\u003c/p\u003e \u003cp\u003eAdditional methodological concerns arise in statistical analysis of the included studies. Long follow-up times introduce competing events like death, potentially impacting the event of interest (e.g., AD diagnosis). The widely used Cox model is not suitable for handling competing risks properly, as it treats them as censored, potentially yielding biased results when the assumption of independent censoring is violated. In contrast, the Fine-Gray model estimates covariate effects on the sub-distribution hazard, offering insights into risk and protective factors' relationships with the event of interest while considering competing risks. Therefore, it is crucial to evaluate study-specific quality indicators, like adherence to the STROBE guidelines, validated outcome measures, and statistical analyses robustness, to prevent overinterpretation of the findings.\u003c/p\u003e \u003cp\u003eLastly, geographic and demographic constraints exist. Despite the extensive data in EHR systems, research is often localized to specific healthcare systems or geographic locales, limiting generalizability. For instance, unlike UK, the US and other countries appear to underutilize national-level EHR datasets. Despite assess to longitudinal EHR datasets across various healthcare systems and regions, research is often confined to specific EHRs. The VHA dataset, though national, predominantly represent male individuals, poses a demographic limitation. Expanding the use of such comprehensive data sources can provide a more representative sample and enhance research generalizability. The lack of research utilizing large, diverse, national EHR datasets underscore the need for future studies on dementia risk through such resources.\u003c/p\u003e \u003cp\u003eThe underdiagnosis of MCI and dementia presents a significant challenge in ADRD research, particularly during early stages. Reliance on EHRs for diagnosis can inadvertently contribute to underreporting, affecting the accuracy of prevalence and incidence rates in the literature. This skewing, due to EHR-based data extraction, might underestimate the true burden of these conditions. Consequently, such underestimation can impact systematic or scoping review findings, altering our understanding of risk factors, disease progression, and intervention effectiveness. Interestingly, individuals frequently interacting with psychiatric services for other conditions are more likely to have cognitive impairment noted in their EHRs compared to those without psychiatric conditions. Therefore, studies that consider psychiatric conditions as risk factors for ADRD particularly require careful interpretation.\u003c/p\u003e \u003cdiv id=\"Sec20\" class=\"Section2\"\u003e \u003ch2\u003eFuture directions\u003c/h2\u003e \u003cp\u003eThe analysis of the articles suggests several avenues for future investigation using EHR data.\u003c/p\u003e \u003cp\u003e \u003col\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eMedical interventions: The impact of medical treatments on reducing cognitive decline in the context of various medical conditions remains unclear. There is a lack of research on pharmacological and surgical effects compared to studies on medical conditions and ADRD. Future research should prioritize studying the relationship between medical interventions and cognitive decline more broadly.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eExplore overlooked factors: investigate additional risk or protective factors, like genetic markers (e.g., apolipoprotein E, presenilin 1 and 2, and amyloid precursor protein), environmental toxins (e.g., lead, pesticides),\u003csup\u003e\u003cspan citationid=\"CR93\" class=\"CitationRef\"\u003e93\u003c/span\u003e\u003c/sup\u003e mild traumatic brain injury,\u003csup\u003e\u003cspan citationid=\"CR94\" class=\"CitationRef\"\u003e94\u003c/span\u003e\u003c/sup\u003e endocrine factors (such as hypothyroidism), sleep disturbance (like sleep apnea or chronic sleep deprivation),\u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR95\" class=\"CitationRef\"\u003e95\u003c/span\u003e\u003c/sup\u003e bilingualism,\u003csup\u003e\u003cspan citationid=\"CR96\" class=\"CitationRef\"\u003e96\u003c/span\u003e\u003c/sup\u003e vitamin and nutritional deficiencies,\u003csup\u003e\u003cspan citationid=\"CR97\" class=\"CitationRef\"\u003e97\u003c/span\u003e\u003c/sup\u003e and the microbiome (e.g., gut microbiome).\u003csup\u003e\u003cspan citationid=\"CR98\" class=\"CitationRef\"\u003e98\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eClinical notes and AI: Almost all the reviewed articles have used data from structured fields of the EHR. Certain conditions and symptoms (e.g., hearing loss, sleep disturbances) that are not consistently captured in structured EHR data may require the examination of clinical notes to identify them, often necessitating AI and natural language processing.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eEarly cognitive decline: While the existing literature primary focuses on dementia or AD, fewer studies address the early onset of AD and the initial stages of cognitive decline, such as mild cognitive impairment and subjective cognitive decline.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eDiversify study populations: Most EHR-based studies have focused on populations with well-defined medical conditions like diabetes, hypertension, cancer, and HIV. To advance research, it\u0026rsquo;s essential to include a broader range of specific groups, such as sexual and gender minorities,\u003csup\u003e\u003cspan citationid=\"CR99\" class=\"CitationRef\"\u003e99\u003c/span\u003e, \u003cspan citationid=\"CR100\" class=\"CitationRef\"\u003e100\u003c/span\u003e\u003c/sup\u003e indigenous populations, those resilient to cognitive decline, and various psychiatric cohorts.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eDatabase integration: Integrating diverse EHR database across institutions and locations, like the UK\u0026rsquo;s national datasets, can expand study populations and enhance research generalizability, which is currently underutilized in the US and other countries.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eData linkage: EHRs lack some data and require linkage with other datasets,\u003csup\u003e\u003cspan citationid=\"CR101\" class=\"CitationRef\"\u003e101\u003c/span\u003e\u003c/sup\u003e including insurance claims, genetics, socioeconomic status,\u003csup\u003e\u003cspan citationid=\"CR102\" class=\"CitationRef\"\u003e102\u003c/span\u003e\u003c/sup\u003e lifestyle, crime, and environmental factors (e.g., air pollution, wildfires, climate change, toxic chemicals).\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003c/ol\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec21\" class=\"Section2\"\u003e \u003ch2\u003eLimitations\u003c/h2\u003e \u003cp\u003eThis review has several limitations to acknowledge. First, our search was constrained to three databases, potentially missing relevant studies in other sources. Second, our search term, focused on titles and abstracts, might have overlooked articles using different terminology or mentioning EHR components (e.g., clinical notes) in the \u003cspan refid=\"Sec2\" class=\"InternalRef\"\u003emethods\u003c/span\u003e section. Third, we didn\u0026rsquo;t perform a bias assessment for included observational studies, which is important considering biases in EHR data collection and outcome measures. Fourth, this review doesn\u0026rsquo;t aim to provide a comprehensive overview of ADRD risk factors; instead, it focuses on what has been studied using EHR data. Finally, we refrained from conducting a meta-analysis due to variations in adjusted confounders among studies, complicating cross-study comparisons.\u003c/p\u003e \u003c/div\u003e"},{"header":"CONCLUSION","content":"\u003cp\u003eEHR data, with its rich and diverse longitudinal real-world information, provides substantial insights into the medical conditions, interventions, lifestyle, socioeconomic, and environmental factors associated with ADRD risk. Looking ahead, research should focus on diversifying study populations and integrating EHR data across geographical locations and with non-EHR datasets. There is also a need to enhance the extraction of information from unstructured text to explore a broader range of risk factors for ADRD.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cp\u003eelectronic health records (EHR), Alzheimer\u0026apos;s disease (AD), mild cognitive impairment (MCI), Alzheimer\u0026apos;s disease and related dementias (ADRD), Strengthening the Reporting of Observational Studies in Epidemiology (STROBE), Veterans Health Administration (VHA), Lewy body dementia (LBD), frontotemporal dementia (FTD), symptomatic Herpes Simplex Virus 1 (HSV-1), Herpes Zoster (HZ), Short Physical Performance Battery (SPPB), nonsteroidal anti-inflammatory drugs (NSAIDs), selective serotonin reuptake inhibitor (SSRI), propensity score matching (PSM), inverse probability weighting (IPW)\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate:\u0026nbsp;\u003c/strong\u003eNot applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication:\u0026nbsp;\u003c/strong\u003eNot applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials:\u0026nbsp;\u003c/strong\u003eThis article is a literature review and does not involve the generation of new data. All data and materials used in this review are derived from publicly available sources and previously published literature. References to these sources are provided within the manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors' contributions:\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eConceptualization: Wang, Yang\u0026nbsp;\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eData curation: Wang, Yang, Sha, Kuraszkiewicz, Leonik\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eFormal analysis: Wang, Yang, Sha, Leonik, Marshall\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eInvestigation: All authors\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eMethodology: Wang, Yang\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eProject administration: Wang, Yang\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eSupervision: Wang, Zhou, Marshall\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eRoles/Writing - original draft: Wang, Yang\u0026nbsp;\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eWriting - review \u0026amp; editing: All authors\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eFunding acquisition: Wang\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eResources: Wang, Zhou\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e: Authors have nothing to disclose.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e: LW and RY are supported by the National Institutes of Health grants K99AG075190 and Alzheimer’s Association Research Fellowship grant AARF-22-924992. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements:\u0026nbsp;\u003c/strong\u003eNot applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDeclaration of Generative AI and AI-assisted technologies in the writing process\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eDuring the preparation of this work the authors used GPT-4 in order to improve the readability and language. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.\u003c/em\u003e\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eJack Jr CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u0026apos;s disease. \u003cem\u003eAlzheimer\u0026apos;s \u0026amp; Dementia\u003c/em\u003e 2018; 14: 535-562.\u003c/li\u003e\n\u003cli\u003eSperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer\u0026rsquo;s disease: Recommendations from the National Institute on Aging-Alzheimer\u0026apos;s Association workgroups on diagnostic guidelines for Alzheimer\u0026apos;s disease. \u003cem\u003eAlzheimer\u0026apos;s \u0026amp; dementia\u003c/em\u003e 2011; 7: 280-292.\u003c/li\u003e\n\u003cli\u003eAssociation As. 2023 Alzheimer\u0026apos;s disease facts and figures. \u003cem\u003eAlzheimer\u0026apos;s \u0026amp; dementia\u003c/em\u003e 2023; 19. DOI: 10.1002/alz.13016.\u003c/li\u003e\n\u003cli\u003eVeitch DP, Weiner MW, Aisen PS, et al. Using the Alzheimer\u0026apos;s Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer\u0026apos;s disease. \u003cem\u003eAlzheimers Dement\u003c/em\u003e 2022; 18: 824-857. 2021/09/29. DOI: 10.1002/alz.12422.\u003c/li\u003e\n\u003cli\u003eDagley A, LaPoint M, Huijbers W, et al. Harvard aging brain study: dataset and accessibility. \u003cem\u003eNeuroimage\u003c/em\u003e 2017; 144: 255-258.\u003c/li\u003e\n\u003cli\u003eWolters FJ, Segufa RA, Darweesh SKL, et al. Coronary heart disease, heart failure, and the risk of dementia: A systematic review and meta-analysis. \u003cem\u003eAlzheimers Dement\u003c/em\u003e 2018; 14: 1493-1504. 2018/03/02. DOI: 10.1016/j.jalz.2018.01.007.\u003c/li\u003e\n\u003cli\u003eShi L, Chen SJ, Ma MY, et al. Sleep disturbances increase the risk of dementia: A systematic review and meta-analysis. \u003cem\u003eSleep Med Rev\u003c/em\u003e 2018; 40: 4-16. 2017/09/12. DOI: 10.1016/j.smrv.2017.06.010.\u003c/li\u003e\n\u003cli\u003eKuiper JS, Zuidersma M, Oude Voshaar RC, et al. Social relationships and risk of dementia: A systematic review and meta-analysis of longitudinal cohort studies. \u003cem\u003eAgeing Res Rev\u003c/em\u003e 2015; 22: 39-57. 2015/05/10. DOI: 10.1016/j.arr.2015.04.006.\u003c/li\u003e\n\u003cli\u003ePage MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. \u003cem\u003eInternational journal of surgery\u003c/em\u003e 2021; 88: 105906.\u003c/li\u003e\n\u003cli\u003eKnottnerus A and Tugwell P. STROBE--a checklist to Strengthen the Reporting of Observational Studies in Epidemiology. \u003cem\u003eJ Clin Epidemiol\u003c/em\u003e 2008; 61: 323. 2008/03/04. DOI: 10.1016/j.jclinepi.2007.11.006.\u003c/li\u003e\n\u003cli\u003eCox DR. Regression models and life‐tables. \u003cem\u003eJournal of the Royal Statistical Society: Series B (Methodological)\u003c/em\u003e 1972; 34: 187-202.\u003c/li\u003e\n\u003cli\u003eFine JP and Gray RJ. A proportional hazards model for the subdistribution of a competing risk. \u003cem\u003eJournal of the American statistical association\u003c/em\u003e 1999; 94: 496-509.\u003c/li\u003e\n\u003cli\u003eFord AH, Yeap BB, Flicker L, et al. Sex hormones and incident dementia in older men: The health in men study. \u003cem\u003ePsychoneuroendocrinology\u003c/em\u003e 2018; 98: 139-147. 2018/08/26. DOI: 10.1016/j.psyneuen.2018.08.013.\u003c/li\u003e\n\u003cli\u003eAlmeida OP, Hankey GJ, Yeap BB, et al. Depression as a risk factor for cognitive impairment in later life: the Health In Men cohort study. \u003cem\u003eInt J Geriatr Psychiatry\u003c/em\u003e 2016; 31: 412-420. 2015/08/19. DOI: 10.1002/gps.4347.\u003c/li\u003e\n\u003cli\u003eAlmeida OP, Ford AH, Hankey GJ, et al. Risk of dementia associated with psychotic disorders in later life: the health in men study (HIMS). \u003cem\u003ePsychol Med\u003c/em\u003e 2019; 49: 232-242. 2018/03/23. DOI: 10.1017/s003329171800065x.\u003c/li\u003e\n\u003cli\u003eLee CH, Lui DTW, Cheung CYY, et al. Different glycaemia-related risk factors for incident Alzheimer\u0026apos;s disease in men and women with type 2 diabetes-A sex-specific analysis of the Hong Kong diabetes database. \u003cem\u003eDiabetes Metab Res Rev\u003c/em\u003e 2021; 37: e3401. 2020/09/02. DOI: 10.1002/dmrr.3401.\u003c/li\u003e\n\u003cli\u003eHsu WWQ, Zhang X, Sing CW, et al. Hip Fracture as a Predictive Marker for the Risk of Dementia: A Population-Based Cohort Study. \u003cem\u003eJ Am Med Dir Assoc\u003c/em\u003e 2022; 23: 1720 e1721-1720 e1729. 2022/08/22. DOI: 10.1016/j.jamda.2022.07.013.\u003c/li\u003e\n\u003cli\u003eCui S, Fang F, Cui P, et al. Associations between the use of beta-adrenoceptor acting drugs and the risk of dementia in older population. \u003cem\u003eFront Neurol\u003c/em\u003e 2022; 13: 999666. 2023/01/10. DOI: 10.3389/fneur.2022.999666.\u003c/li\u003e\n\u003cli\u003eSchnier C, Janbek J, Williams L, et al. Antiherpetic medication and incident dementia: Observational cohort studies in four countries. \u003cem\u003eEur J Neurol\u003c/em\u003e 2021; 28: 1840-1848. 2021/03/04. DOI: 10.1111/ene.14795.\u003c/li\u003e\n\u003cli\u003ePerera G, Rijnbeek PR, Alexander M, et al. Vascular and metabolic risk factor differences prior to dementia diagnosis: a multidatabase case-control study using European electronic health records. \u003cem\u003eBMJ Open\u003c/em\u003e 2020; 10: e038753. 2020/11/17. DOI: 10.1136/bmjopen-2020-038753.\u003c/li\u003e\n\u003cli\u003eNewby D, Prieto-Alhambra D, Duarte-Salles T, et al. Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study. \u003cem\u003eAlzheimers Res Ther\u003c/em\u003e 2020; 12: 38. 2020/04/08. DOI: 10.1186/s13195-020-00606-5.\u003c/li\u003e\n\u003cli\u003eHafdi M, Hoevenaar-Blom MP, Beishuizen CRL, et al. Association of Benzodiazepine and Anticholinergic Drug Usage With Incident Dementia: A Prospective Cohort Study of Community-Dwelling Older Adults. \u003cem\u003eJ Am Med Dir Assoc\u003c/em\u003e 2020; 21: 188-193.e183. 2019/07/14. DOI: 10.1016/j.jamda.2019.05.010.\u003c/li\u003e\n\u003cli\u003eKuo SC, Lai SW, Hung HC, et al. Association between comorbidities and dementia in diabetes mellitus patients: population-based retrospective cohort study. \u003cem\u003eJ Diabetes Complications\u003c/em\u003e 2015; 29: 1071-1076. 2015/08/04. DOI: 10.1016/j.jdiacomp.2015.06.010.\u003c/li\u003e\n\u003cli\u003eLiu CH, Sung PS, Li YR, et al. Telmisartan use and risk of dementia in type 2 diabetes patients with hypertension: A population-based cohort study. \u003cem\u003ePLoS Med\u003c/em\u003e 2021; 18: e1003707. 2021/07/20. DOI: 10.1371/journal.pmed.1003707.\u003c/li\u003e\n\u003cli\u003ePapadopoulos E, Abu Helal A, Berger A, et al. Objective measures of physical function and their association with cognitive impairment in older adults with cancer prior to treatment. \u003cem\u003eJ Geriatr Oncol\u003c/em\u003e 2022; 13: 1141-1148. 2022/07/26. DOI: 10.1016/j.jgo.2022.07.007.\u003c/li\u003e\n\u003cli\u003ePham ANQ, Lindeman C, Voaklander D, et al. Risk factors for incidence of dementia in primary care practice: a retrospective cohort study in older adults. \u003cem\u003eFam Pract\u003c/em\u003e 2022; 39: 406-412. 2021/12/16. DOI: 10.1093/fampra/cmab168.\u003c/li\u003e\n\u003cli\u003eHalliday A, Sneade M, Bj\u0026ouml;rck M, et al. Editor\u0026apos;s Choice - Effect of Carotid Endarterectomy on 20 Year Incidence of Recorded Dementia: A Randomised Trial. \u003cem\u003eEur J Vasc Endovasc Surg\u003c/em\u003e 2022; 63: 535-545. 2022/03/12. DOI: 10.1016/j.ejvs.2021.12.041.\u003c/li\u003e\n\u003cli\u003eKivim\u0026auml;ki M, Singh-Manoux A, Batty GD, et al. Association of Alcohol-Induced Loss of Consciousness and Overall Alcohol Consumption With Risk for Dementia. \u003cem\u003eJAMA Netw Open\u003c/em\u003e 2020; 3: e2016084. 2020/09/10. DOI: 10.1001/jamanetworkopen.2020.16084.\u003c/li\u003e\n\u003cli\u003eWang L, Davis PB, Volkow ND, et al. Association of COVID-19 with New-Onset Alzheimer\u0026apos;s Disease. \u003cem\u003eJ Alzheimers Dis\u003c/em\u003e 2022; 89: 411-414. 2022/08/02. DOI: 10.3233/jad-220717.\u003c/li\u003e\n\u003cli\u003eGorenflo MP, Davis PB, Kendall EK, et al. Association of Aspirin Use with Reduced Risk of Developing Alzheimer\u0026apos;s Disease in Elderly Ischemic Stroke Patients: A Retrospective Cohort Study. \u003cem\u003eJ Alzheimers Dis\u003c/em\u003e 2023; 91: 697-704. 2022/12/12. DOI: 10.3233/jad-220901.\u003c/li\u003e\n\u003cli\u003eProietti R, Rivera-Caravaca JM, L\u0026oacute;pez-G\u0026aacute;lvez R, et al. Cerebrovascular, Cognitive and Cardiac Benefits of SGLT2 Inhibitors Therapy in Patients with Atrial Fibrillation and Type 2 Diabetes Mellitus: Results from a Global Federated Health Network Analysis. \u003cem\u003eJ Clin Med\u003c/em\u003e 2023; 12 2023/04/28. DOI: 10.3390/jcm12082814.\u003c/li\u003e\n\u003cli\u003eAggarwal M, Alkhayyat M, Abou Saleh M, et al. Alzheimer Disease Occurs More Frequently In Patients With Inflammatory Bowel Disease: Insight From a Nationwide Study. \u003cem\u003eJ Clin Gastroenterol\u003c/em\u003e 2023; 57: 501-507. 2022/04/27. DOI: 10.1097/mcg.0000000000001714.\u003c/li\u003e\n\u003cli\u003eNewby D, Linden AB, Fernandes M, et al. Comparative effect of metformin versus sulfonylureas with dementia and Parkinson\u0026apos;s disease risk in US patients over 50 with type 2 diabetes mellitus. \u003cem\u003eBMJ Open Diabetes Res Care\u003c/em\u003e 2022; 10 2022/09/16. DOI: 10.1136/bmjdrc-2022-003036.\u003c/li\u003e\n\u003cli\u003eLindbohm JV, Mars N, Walker KA, et al. Plasma proteins, cognitive decline, and 20-year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies. \u003cem\u003eAlzheimers Dement\u003c/em\u003e 2022; 18: 612-624. 2021/08/03. DOI: 10.1002/alz.12419.\u003c/li\u003e\n\u003cli\u003eBarbiellini Amidei C, Fayosse A, Dumurgier J, et al. Association Between Age at Diabetes Onset and Subsequent Risk of Dementia. \u003cem\u003eJama\u003c/em\u003e 2021; 325: 1640-1649. 2021/04/28. DOI: 10.1001/jama.2021.4001.\u003c/li\u003e\n\u003cli\u003eSingh-Manoux A, Oumarou-Ibrahim A, Machado-Fragua MD, et al. Association between kidney function and incidence of dementia: 10-year follow-up of the Whitehall II cohort study. \u003cem\u003eAge Ageing\u003c/em\u003e 2022; 51 2022/01/22. DOI: 10.1093/ageing/afab259.\u003c/li\u003e\n\u003cli\u003eAkbaraly TN, Singh-Manoux A, Dugravot A, et al. Association of Midlife Diet With Subsequent Risk for Dementia. \u003cem\u003eJama\u003c/em\u003e 2019; 321: 957-968. 2019/03/13. DOI: 10.1001/jama.2019.1432.\u003c/li\u003e\n\u003cli\u003eRusmaully J, Dugravot A, Moatti JP, et al. Contribution of cognitive performance and cognitive decline to associations between socioeconomic factors and dementia: A cohort study. \u003cem\u003ePLoS Med\u003c/em\u003e 2017; 14: e1002334. 2017/06/27. DOI: 10.1371/journal.pmed.1002334.\u003c/li\u003e\n\u003cli\u003eSommerlad A, Sabia S, Singh-Manoux A, et al. Association of social contact with dementia and cognition: 28-year follow-up of the Whitehall II cohort study. \u003cem\u003ePLoS Med\u003c/em\u003e 2019; 16: e1002862. 2019/08/03. DOI: 10.1371/journal.pmed.1002862.\u003c/li\u003e\n\u003cli\u003eCao Z, Xu C, Yang H, et al. Associations of BMI and Serum Urate with Developing Dementia: A Prospective Cohort Study. \u003cem\u003eJ Clin Endocrinol Metab\u003c/em\u003e 2020; 105 2020/09/13. DOI: 10.1210/clinem/dgaa638.\u003c/li\u003e\n\u003cli\u003eLittlejohns TJ, Hayat S, Luben R, et al. Visual Impairment and Risk of Dementia in 2 Population-Based Prospective Cohorts: UK Biobank and EPIC-Norfolk. \u003cem\u003eJ Gerontol A Biol Sci Med Sci\u003c/em\u003e 2022; 77: 697-704. 2021/11/01. DOI: 10.1093/gerona/glab325.\u003c/li\u003e\n\u003cli\u003eMuzambi R, Bhaskaran K, Rentsch CT, et al. Are infections associated with cognitive decline and neuroimaging outcomes? A historical cohort study using data from the UK Biobank study linked to electronic health records. \u003cem\u003eTransl Psychiatry\u003c/em\u003e 2022; 12: 385. 2022/09/16. DOI: 10.1038/s41398-022-02145-z.\u003c/li\u003e\n\u003cli\u003eGeng T, Lu Q, Wan Z, et al. Association of serum 25-hydroxyvitamin D concentrations with risk of dementia among individuals with type 2 diabetes: A cohort study in the UK Biobank. \u003cem\u003ePLoS Med\u003c/em\u003e 2022; 19: e1003906. 2022/01/14. DOI: 10.1371/journal.pmed.1003906.\u003c/li\u003e\n\u003cli\u003eWang B, Wang N, Sun Y, et al. Association of Combined Healthy Lifestyle Factors With Incident Dementia in Patients With Type 2 Diabetes. \u003cem\u003eNeurology\u003c/em\u003e 2022; 99: e2336-e2345. 2022/09/15. DOI: 10.1212/wnl.0000000000201231.\u003c/li\u003e\n\u003cli\u003eKhondoker M, Macgregor A, Bachmann MO, et al. Multimorbidity pattern and risk of dementia in later life: an 11-year follow-up study using a large community cohort and linked electronic health records. \u003cem\u003eJ Epidemiol Community Health\u003c/em\u003e 2023; 77: 285-292. 2023/03/09. DOI: 10.1136/jech-2022-220034.\u003c/li\u003e\n\u003cli\u003eElovainio M, Lahti J, Pirinen M, et al. Association of social isolation, loneliness and genetic risk with incidence of dementia: UK Biobank Cohort Study. \u003cem\u003eBMJ Open\u003c/em\u003e 2022; 12: e053936. 2022/02/25. DOI: 10.1136/bmjopen-2021-053936.\u003c/li\u003e\n\u003cli\u003eHerbert A, Wijlaars L, Zylbersztejn A, et al. Data resource profile: hospital episode statistics admitted patient care (HES APC). \u003cem\u003eInternational journal of epidemiology\u003c/em\u003e 2017; 46: 1093-1093i.\u003c/li\u003e\n\u003cli\u003eHarley K and Jones C. Quality of Scottish morbidity record (SMR) data. \u003cem\u003eHealth bulletin\u003c/em\u003e 1996; 54: 410-417.\u003c/li\u003e\n\u003cli\u003eMehta HB, Mehta V and Goodwin JS. Association of Hypoglycemia With Subsequent Dementia in Older Patients With Type 2 Diabetes Mellitus. \u003cem\u003eJ Gerontol A Biol Sci Med Sci\u003c/em\u003e 2017; 72: 1110-1116. 2016/10/28. DOI: 10.1093/gerona/glw217.\u003c/li\u003e\n\u003cli\u003eWarren-Gash C, Williamson E, Shiekh SI, et al. No evidence that herpes zoster is associated with increased risk of dementia diagnosis. \u003cem\u003eAnn Clin Transl Neurol\u003c/em\u003e 2022; 9: 363-374. 2022/02/17. DOI: 10.1002/acn3.51525.\u003c/li\u003e\n\u003cli\u003eDregan A, Chowienczyk P and Armstrong D. Patterns of anti-inflammatory drug use and risk of dementia: a matched case-control study. \u003cem\u003eEur J Neurol\u003c/em\u003e 2015; 22: 1421-1428. 2015/07/16. DOI: 10.1111/ene.12774.\u003c/li\u003e\n\u003cli\u003eCadogan SL, Powell E, Wing K, et al. Anticoagulant prescribing for atrial fibrillation and risk of incident dementia. \u003cem\u003eHeart\u003c/em\u003e 2021; 107: 1898-1904. 2021/10/15. DOI: 10.1136/heartjnl-2021-319672.\u003c/li\u003e\n\u003cli\u003eFloud S, Simpson RF, Balkwill A, et al. Body mass index, diet, physical inactivity, and the incidence of dementia in 1 million UK women. \u003cem\u003eNeurology\u003c/em\u003e 2020; 94: e123-e132. 2019/12/20. DOI: 10.1212/WNL.0000000000008779.\u003c/li\u003e\n\u003cli\u003eBrauer R, Lau WCY, Hayes JF, et al. Trazodone use and risk of dementia: A population-based cohort study. \u003cem\u003ePLoS Med\u003c/em\u003e 2019; 16: e1002728. 2019/02/06. DOI: 10.1371/journal.pmed.1002728.\u003c/li\u003e\n\u003cli\u003eLu N, Dubreuil M, Zhang Y, et al. Gout and the risk of Alzheimer\u0026apos;s disease: a population-based, BMI-matched cohort study. \u003cem\u003eAnn Rheum Dis\u003c/em\u003e 2016; 75: 547-551. 2015/03/06. DOI: 10.1136/annrheumdis-2014-206917.\u003c/li\u003e\n\u003cli\u003eHendrie HC, Zheng M, Li W, et al. Glucose level decline precedes dementia in elderly African Americans with diabetes. \u003cem\u003eAlzheimers Dement\u003c/em\u003e 2017; 13: 111-118. 2016/10/30. DOI: 10.1016/j.jalz.2016.08.017.\u003c/li\u003e\n\u003cli\u003eLee CS, Gibbons LE, Lee AY, et al. Association Between Cataract Extraction and Development of Dementia. \u003cem\u003eJAMA Intern Med\u003c/em\u003e 2022; 182: 134-141. 2021/12/07. DOI: 10.1001/jamainternmed.2021.6990.\u003c/li\u003e\n\u003cli\u003eLee CS, Lee ML, Gibbons LE, et al. Associations Between Retinal Artery/Vein Occlusions and Risk of Vascular Dementia. \u003cem\u003eJ Alzheimers Dis\u003c/em\u003e 2021; 81: 245-253. 2021/03/23. DOI: 10.3233/jad-201492.\u003c/li\u003e\n\u003cli\u003eIbler E, Tran G, Orrell KA, et al. Inverse association for diagnosis of Alzheimer\u0026apos;s disease subsequent to both melanoma and non-melanoma skin cancers in a large, urban, single-centre, Midwestern US patient population. \u003cem\u003eJ Eur Acad Dermatol Venereol\u003c/em\u003e 2018; 32: 1893-1896. 2018/03/25. DOI: 10.1111/jdv.14952.\u003c/li\u003e\n\u003cli\u003eDoney ASF, Bonney W, Jefferson E, et al. Investigating the Relationship Between Type 2 Diabetes and Dementia Using Electronic Medical Records in the GoDARTS Bioresource. \u003cem\u003eDiabetes Care\u003c/em\u003e 2019; 42: 1973-1980. 2019/08/09. DOI: 10.2337/dc19-0380.\u003c/li\u003e\n\u003cli\u003eNagar SD, Pemu P, Qian J, et al. Investigation of hypertension and type 2 diabetes as risk factors for dementia in the All of Us cohort. \u003cem\u003eSci Rep\u003c/em\u003e 2022; 12: 19797. 2022/11/18. DOI: 10.1038/s41598-022-23353-z.\u003c/li\u003e\n\u003cli\u003eHendrie HC, Zheng M, Lane KA, et al. Changes of glucose levels precede dementia in African-Americans with diabetes but not in Caucasians. \u003cem\u003eAlzheimers Dement\u003c/em\u003e 2018; 14: 1572-1579. 2018/04/22. DOI: 10.1016/j.jalz.2018.03.008.\u003c/li\u003e\n\u003cli\u003eGilsanz P, Mayeda ER, Glymour MM, et al. Female sex, early-onset hypertension, and risk of dementia. \u003cem\u003eNeurology\u003c/em\u003e 2017; 89: 1886-1893. 2017/10/06. DOI: 10.1212/wnl.0000000000004602.\u003c/li\u003e\n\u003cli\u003eAbell JG, Kivim\u0026auml;ki M, Dugravot A, et al. Association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension. \u003cem\u003eEur Heart J\u003c/em\u003e 2018; 39: 3119-3125. 2018/06/15. DOI: 10.1093/eurheartj/ehy288.\u003c/li\u003e\n\u003cli\u003eWhiteley WN, Gupta AK, Godec T, et al. Long-Term Incidence of Stroke and Dementia in ASCOT. \u003cem\u003eStroke\u003c/em\u003e 2021; 52: 3088-3096. 2021/07/02. DOI: 10.1161/strokeaha.120.033489.\u003c/li\u003e\n\u003cli\u003eBobrow K, Xia F, Hoang T, et al. HIV and risk of dementia in older veterans. \u003cem\u003eAids\u003c/em\u003e 2020; 34: 1673-1679. 2020/07/24. DOI: 10.1097/qad.0000000000002597.\u003c/li\u003e\n\u003cli\u003eLam JO, Hou CE, Hojilla JC, et al. Comparison of dementia risk after age 50 between individuals with and without HIV infection. \u003cem\u003eAIDS\u003c/em\u003e 2021; 35: 821-828. 2021/01/05. DOI: 10.1097/QAD.0000000000002806.\u003c/li\u003e\n\u003cli\u003eKatz J and Gao H. The Alzheimer-E. coli Axis: What Can We Learn from an Electronic Health Record Platform. \u003cem\u003eJ Alzheimers Dis\u003c/em\u003e 2021; 84: 717-721. 2021/09/28. DOI: 10.3233/jad-215004.\u003c/li\u003e\n\u003cli\u003eYoung-Xu Y, Powell EI, Zwain GM, et al. Symptomatic Herpes Simplex Virus Infection and Risk of Dementia in US Veterans: a Cohort Study. \u003cem\u003eNeurotherapeutics\u003c/em\u003e 2021; 18: 2458-2467. 2021/07/11. DOI: 10.1007/s13311-021-01084-9.\u003c/li\u003e\n\u003cli\u003eGilsanz P, Schnaider Beeri M, Karter AJ, et al. Depression in type 1 diabetes and risk of dementia. \u003cem\u003eAging Ment Health\u003c/em\u003e 2019; 23: 880-886. 2018/04/11. DOI: 10.1080/13607863.2018.1455167.\u003c/li\u003e\n\u003cli\u003eChan AX, Bakhoum CY, Bangen KJ, et al. Relationship between Retinal Vascular Occlusions and Cognitive Dementia in a Large Cross-Sectional Cohort. \u003cem\u003eAm J Ophthalmol\u003c/em\u003e 2021; 226: 201-205. 2021/02/03. DOI: 10.1016/j.ajo.2021.01.026.\u003c/li\u003e\n\u003cli\u003eExalto LG, Biessels GJ, Karter AJ, et al. Severe diabetic retinal disease and dementia risk in type 2 diabetes. \u003cem\u003eJ Alzheimers Dis\u003c/em\u003e 2014; 42 Suppl 3: S109-117. 2014/03/15. DOI: 10.3233/jad-132570.\u003c/li\u003e\n\u003cli\u003eRodill LG, Exalto LG, Gilsanz P, et al. Diabetic Retinopathy and Dementia in Type 1 Diabetes. \u003cem\u003eAlzheimer Dis Assoc Disord\u003c/em\u003e 2018; 32: 125-130. 2017/12/21. DOI: 10.1097/wad.0000000000000230.\u003c/li\u003e\n\u003cli\u003eBarnes DE, Kaup A, Kirby KA, et al. Traumatic brain injury and risk of dementia in older veterans. \u003cem\u003eNeurology\u003c/em\u003e 2014; 83: 312-319. 2014/06/27. DOI: 10.1212/wnl.0000000000000616.\u003c/li\u003e\n\u003cli\u003eKim Y, Lhatoo S, Zhang GQ, et al. Temporal phenotyping for transitional disease progress: An application to epilepsy and Alzheimer\u0026apos;s disease. \u003cem\u003eJ Biomed Inform\u003c/em\u003e 2020; 107: 103462. 2020/06/21. DOI: 10.1016/j.jbi.2020.103462.\u003c/li\u003e\n\u003cli\u003eXu J, Wang F, Zang C, et al. Comparing the effects of four common drug classes on the progression of mild cognitive impairment to dementia using electronic health records. \u003cem\u003eSci Rep\u003c/em\u003e 2023; 13: 8102. 2023/05/20. DOI: 10.1038/s41598-023-35258-6.\u003c/li\u003e\n\u003cli\u003eSalas J, Morley JE, Scherrer JF, et al. Risk of incident dementia following metformin initiation compared with noninitiation or delay of antidiabetic medication therapy. \u003cem\u003ePharmacoepidemiol Drug Saf\u003c/em\u003e 2020; 29: 623-634. 2020/05/05. DOI: 10.1002/pds.5014.\u003c/li\u003e\n\u003cli\u003eTang X, Brinton RD, Chen Z, et al. Use of oral diabetes medications and the risk of incident dementia in US veterans aged \u0026ge;60 years with type 2 diabetes. \u003cem\u003eBMJ Open Diabetes Res Care\u003c/em\u003e 2022; 10 2022/10/12. DOI: 10.1136/bmjdrc-2022-002894.\u003c/li\u003e\n\u003cli\u003eKim J, Kelley J, Kleinschmit K, et al. Development of dementia in patients who underwent bariatric surgery. \u003cem\u003eSurg Endosc\u003c/em\u003e 2023; 37: 3507-3521. 2022/12/30. DOI: 10.1007/s00464-022-09837-z.\u003c/li\u003e\n\u003cli\u003eZhou M, Xu R, Kaelber DC, et al. Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer\u0026apos;s disease in patients with rheumatoid arthritis and psoriasis. \u003cem\u003ePLoS One\u003c/em\u003e 2020; 15: e0229819. 2020/03/24. DOI: 10.1371/journal.pone.0229819.\u003c/li\u003e\n\u003cli\u003eWang C, Gao S, Hendrie HC, et al. Antidepressant Use in the Elderly Is Associated With an Increased Risk of Dementia. \u003cem\u003eAlzheimer Dis Assoc Disord\u003c/em\u003e 2016; 30: 99-104. 2015/08/22. DOI: 10.1097/wad.0000000000000103.\u003c/li\u003e\n\u003cli\u003eNead KT, Gaskin G, Chester C, et al. Androgen Deprivation Therapy and Future Alzheimer\u0026apos;s Disease Risk. \u003cem\u003eJ Clin Oncol\u003c/em\u003e 2016; 34: 566-571. 2015/12/09. DOI: 10.1200/jco.2015.63.6266.\u003c/li\u003e\n\u003cli\u003eNead KT, Gaskin G, Chester C, et al. Association Between Androgen Deprivation Therapy and Risk of Dementia. \u003cem\u003eJAMA Oncol\u003c/em\u003e 2017; 3: 49-55. 2016/10/14. DOI: 10.1001/jamaoncol.2016.3662.\u003c/li\u003e\n\u003cli\u003eBromley SE, Matthews A, Smeeth L, et al. Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK. \u003cem\u003eJ Cancer Surviv\u003c/em\u003e 2019; 13: 632-640. 2019/07/20. DOI: 10.1007/s11764-019-00782-w.\u003c/li\u003e\n\u003cli\u003eFlores AC, Jensen GL, Mitchell DC, et al. Prospective Study of Diet Quality and the Risk of Dementia in the Oldest Old. \u003cem\u003eNutrients\u003c/em\u003e 2023; 15 2023/03/12. DOI: 10.3390/nu15051282.\u003c/li\u003e\n\u003cli\u003eSoh Y, Whitmer RA, Mayeda ER, et al. State-Level Indicators of Childhood Educational Quality and Incident Dementia in Older Black and White Adults. \u003cem\u003eJAMA Neurol\u003c/em\u003e 2023; 80: 352-359. 2023/02/14. DOI: 10.1001/jamaneurol.2022.5337.\u003c/li\u003e\n\u003cli\u003eHayes-Larson E, Ikesu R, Fong J, et al. Association of Education With Dementia Incidence Stratified by Ethnicity and Nativity in a Cohort of Older Asian American Individuals. \u003cem\u003eJAMA Netw Open\u003c/em\u003e 2023; 6: e231661. 2023/03/07. DOI: 10.1001/jamanetworkopen.2023.1661.\u003c/li\u003e\n\u003cli\u003eBecerril A, Pfoh ER, Hashmi AZ, et al. Racial, ethnic and neighborhood socioeconomic differences in incidence of dementia: A regional retrospective cohort study. \u003cem\u003eJ Am Geriatr Soc\u003c/em\u003e 2023 2023/03/18. DOI: 10.1111/jgs.18322.\u003c/li\u003e\n\u003cli\u003eGilsanz P, Mayeda ER, Glymour MM, et al. Association Between Birth in a High Stroke Mortality State, Race, and Risk of Dementia. \u003cem\u003eJAMA Neurol\u003c/em\u003e 2017; 74: 1056-1062. 2017/08/02. DOI: 10.1001/jamaneurol.2017.1553.\u003c/li\u003e\n\u003cli\u003eMartinez S, Yaffe K, Li Y, et al. Agent Orange Exposure and Dementia Diagnosis in US Veterans of the Vietnam Era. \u003cem\u003eJAMA Neurol\u003c/em\u003e 2021; 78: 473-477. 2021/01/26. DOI: 10.1001/jamaneurol.2020.5011.\u003c/li\u003e\n\u003cli\u003eDuthie AC, Hannah J, Batty GD, et al. Low-level lithium in drinking water and subsequent risk of dementia: Cohort study. \u003cem\u003eInt J Geriatr Psychiatry\u003c/em\u003e 2023; 38: e5890. 2023/02/08. DOI: 10.1002/gps.5890.\u003c/li\u003e\n\u003cli\u003eCasey JA, Schwartz BS, Stewart WF, et al. Using Electronic Health Records for Population Health Research: A Review of Methods and Applications. \u003cem\u003eAnnu Rev Public Health\u003c/em\u003e 2016; 37: 61-81. 2015/12/17. DOI: 10.1146/annurev-publhealth-032315-021353.\u003c/li\u003e\n\u003cli\u003eYan D, Zhang Y, Liu L, et al. Pesticide exposure and risk of Alzheimer\u0026apos;s disease: a systematic review and meta-analysis. \u003cem\u003eSci Rep\u003c/em\u003e 2016; 6: 32222. 2016/09/02. DOI: 10.1038/srep32222.\u003c/li\u003e\n\u003cli\u003eClark E, Faruque S, Mutebi C, et al. Investigating the relationship between mild traumatic brain injury and Alzheimer\u0026apos;s disease and related dementias: a systematic review. \u003cem\u003eJ Neurol\u003c/em\u003e 2022; 269: 4635-4645. 2022/06/02. DOI: 10.1007/s00415-022-11186-9.\u003c/li\u003e\n\u003cli\u003eGuay-Gagnon M, Vat S, Forget MF, et al. Sleep apnea and the risk of dementia: A systematic review and meta-analysis. \u003cem\u003eJ Sleep Res\u003c/em\u003e 2022; 31: e13589. 2022/04/03. DOI: 10.1111/jsr.13589.\u003c/li\u003e\n\u003cli\u003eBrini S, Sohrabi HR, Hebert JJ, et al. Bilingualism Is Associated with a Delayed Onset of Dementia but Not with a Lower Risk of Developing it: a Systematic Review with Meta-Analyses. \u003cem\u003eNeuropsychol Rev\u003c/em\u003e 2020; 30: 1-24. 2020/02/10. DOI: 10.1007/s11065-020-09426-8.\u003c/li\u003e\n\u003cli\u003eZhou J, Sun Y, Ji M, et al. Association of Vitamin B Status with Risk of Dementia in Cohort Studies: A Systematic Review and Meta-Analysis. \u003cem\u003eJ Am Med Dir Assoc\u003c/em\u003e 2022; 23: 1826 e1821-1826 e1835. 2022/07/03. DOI: 10.1016/j.jamda.2022.05.022.\u003c/li\u003e\n\u003cli\u003eCoradduzza D, Sedda S, Cruciani S, et al. Age-Related Cognitive Decline, Focus on Microbiome: A Systematic Review and Meta-Analysis. \u003cem\u003eInternational Journal of Molecular Sciences\u003c/em\u003e 2023; 24: 13680.\u003c/li\u003e\n\u003cli\u003eHua Y, Wang L, Nguyen V, et al. A deep learning approach for transgender and gender diverse patient identification in electronic health records. \u003cem\u003eJ Biomed Inform\u003c/em\u003e 2023; 147: 104507. 2023/10/02. DOI: 10.1016/j.jbi.2023.104507.\u003c/li\u003e\n\u003cli\u003eRomanelli RJ, Rosenblatt AS, Marcum ZA, et al. Cognitive Impairment in Sexual and Gender Minority Groups: A Scoping Review of the Literature. \u003cem\u003eLGBT Health\u003c/em\u003e 2023 2023/10/12. DOI: 10.1089/lgbt.2023.0095.\u003c/li\u003e\n\u003cli\u003eDeBord DG, Carreon T, Lentz TJ, et al. Use of the \u0026quot;Exposome\u0026quot; in the Practice of Epidemiology: A Primer on -Omic Technologies. \u003cem\u003eAm J Epidemiol\u003c/em\u003e 2016; 184: 302-314. 2016/08/16. DOI: 10.1093/aje/kwv325.\u003c/li\u003e\n\u003cli\u003eKind AJH and Buckingham WR. Making Neighborhood-Disadvantage Metrics Accessible - The Neighborhood Atlas. \u003cem\u003eN Engl J Med\u003c/em\u003e 2018; 378: 2456-2458. 2018/06/28. DOI: 10.1056/NEJMp1802313.\u003c/li\u003e\n\u003cli\u003eBiondo F, Jewell A, Pritchard M, et al. Brain-age is associated with progression to dementia in memory clinic patients. \u003cem\u003eNeuroimage Clin\u003c/em\u003e 2022; 36: 103175. 2022/09/11. DOI: 10.1016/j.nicl.2022.103175.\u003c/li\u003e\n\u003cli\u003eRuss TC, Hannah J, Batty GD, et al. Childhood Cognitive Ability and Incident Dementia: The 1932 Scottish Mental Survey Cohort into their 10th Decade. \u003cem\u003eEpidemiology\u003c/em\u003e 2017; 28: 361-364. 2017/02/06. DOI: 10.1097/ede.0000000000000626.\u003c/li\u003e\n\u003cli\u003eSchulte PJ, Warner DO, Martin DP, et al. Association Between Critical Care Admissions and Cognitive Trajectories in Older Adults. \u003cem\u003eCrit Care Med\u003c/em\u003e 2019; 47: 1116-1124. 2019/05/21. DOI: 10.1097/ccm.0000000000003829.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Alzheimer Disease, Dementia, Cognitive Dysfunction, Risk Factors, Electronic Health Records","lastPublishedDoi":"10.21203/rs.3.rs-4671544/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4671544/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground\u003c/strong\u003e: The data and information contained within electronic health records (EHR) provide a rich, diverse, longitudinal view of real-world patient histories, offering valuable opportunities to study antecedent risk factors for cognitive decline. However, the extent to which such records’ data have been utilized to elucidate the risk factors of cognitive decline remains unclear.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods\u003c/strong\u003e: A scoping review was conducted following the PRISMA guideline, examining articles published between January 2010 and April 2023, from PubMed, Web of Science, and CINAHL. Inclusion criteria focused on studies using EHR to investigate risk factors for cognitive decline. Each article was screened by at least two reviewers. Data elements were manually extracted based on a predefined schema. The studied risk factors were classified into categories, and a research gap was identified.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults\u003c/strong\u003e: From 1,593 articles identified, 80 were selected. The majority (87.5%) were retrospective cohort studies, with 66.3% using datasets of over 10,000 patients, predominantly from the US or UK. Analysis showed that 48.8% of studies addressed medical conditions, 31.3% focused on medical interventions, and 17.5% on lifestyle, socioeconomic status, and environmental factors. Most studies on medical conditions were linked to an increased risk of cognitive decline, whereas medical interventions addressing these conditions often reduced the risk.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusions\u003c/strong\u003e: EHR data significantly enhanced our understanding of medical conditions, interventions, lifestyle, socioeconomic status, and environmental factors related to the risk of cognitive decline.\u003c/p\u003e","manuscriptTitle":"Assessing Risk Factors for Cognitive Decline Using Electronic Health Record Data: A Scoping Review","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-08-09 21:05:44","doi":"10.21203/rs.3.rs-4671544/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"db1c38be-503f-4119-9384-eb245882f781","owner":[],"postedDate":"August 9th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2025-02-12T15:23:47+00:00","versionOfRecord":[],"versionCreatedAt":"2024-08-09 21:05:44","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4671544","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4671544","identity":"rs-4671544","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}